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ABSTRACT 
 
 
The purpose of this study was to determine the impact of baseline systemic 
inflammation (pro-inflammatory cytokine, anti-inflammatory cytokine, and their ratio), 
genetic variability, and environment on the development of health care associated 
infections (HAI) among sepsis patients during their ICU stay (up to 28 days).  
Methods: A prospective observation study was conducted at the Veterans Affairs 
Medical Center in the Medical Intensive Care Unit over an 18 month period. A total of 78 
patients were enrolled within 72 hours of presenting to the ICU with sepsis. Patient were 
excluded if they were receiving immunosuppressants (chemotherapy or greater than one 
mg/kg of prednisone or equivalent dose), immunosuppressed (AIDS, cancer), or had liver 
failure (Child Pugh category C or higher). Baseline plasma and buccal swabs were 
collected. Patients were followed prospectively through their ICU stay (or for a 
maximum of 28 days) for the development of HAI as defined by CDC guidelines. 
Primary variables included baseline IL-6 and IL-10 levels, IL-6 SNP rs1800795, IL-10 
SNP rs1800896, APACHE II, invasive devices, and development of HAI. 
 
Results: A total of 17 HAI were identified with 64% caused by Candida.  There 
were no significant differences in levels of pro-inflammatory cytokine, anti-inflammatory 
cytokine, or their ratio among subjects who did and did not develop at least one HAI 
during their ICU stay. There were also no significant differences in rs1800795 or 
rs1800896 genotypes for those who did and did not develop HAI; however, racial 
differences were detected in genotypes among white and black patients with sepsis who 
did and did not develop HAI. There was a significant difference in rs1800795 genotype 
among black patients with sepsis who did not develop HAI compared to whites patients 
with sepsis who did not develop HAI (p = 0.006). Specifically, black patients had a lower 
CG (17.4% vs. 42.1%) and higher GG (82.6% vs. 42.1%) than white patients. There were 
no racial differences when comparing white and black sepsis patients who developed 
HAI (p = 1.0).  In a series of Cox regression analyses investigating timing to first HAI 
among those who did and did not develop HAI during ICU stay, the final model included 
only APACHE II, cumulative invasive device score, and IL-6 rs1800795.  
 
Conclusion: This study provides evidence of a genetic risk for development of 
HAI. Despite best evidenced based practices some patients will develop HAI. Strict 
aseptic technique is essential to preventing infection. In addition to eliminating invasive 
devices as quickly as possible, patients with a high severity of illness may need to be 
isolated to lower their risk. Early administration of antibiotics not only provides prompt 
treatment for the initial infection but also lowers risk for subsequent infections.   
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CHAPTER 1.  INTRODUCTION 
 
 
Overview 
 
Health care associated infection (HAI) among patients in the intensive care unit 
(ICU) has been identified as an independent risk factor for hospital mortality.1 Patients 
presenting to the ICU are at high risk for development of HAI 2 which can result in 
prolonged ICU stay, as well as sequelae leading to organ dysfunction and death.2-5 The 
mechanism for development of all HAI is unclear; although, predisposing factors such as 
invasive devices6-8 may be responsible for approximately half of all HAI9 and severity of 
illness is a predisposing factor.9,10  Although the central role of the inflammatory 
response is to control infections, an exaggerated response may also play a role in the 
development of HAI.   
 
Cytokines are proteins that orchestrate the inflammatory response.  The 
inflammatory response begins locally and may become systemic.  There is usually a 
balanced inflammatory response, with pro-inflammatory cytokines (i.e., IL-1β, TNF-α, 
and IL-6) initiating the inflammatory process against infection, and anti-inflammatory 
cytokines (i.e., IL-1ra and  IL-10) functioning to down regulate the inflammatory 
response.11  Systemic inflammation is usually manifested with fever or hypothermia, 
tachycardia, hyperpnea, and leukocytosis or leukopenia.  
 
Baseline severity of illness (measured by APACHE II) correlates with baseline 
inflammatory response and this process is independent of the causative organism.12  The 
relationship between the development of new HAI and the degree of baseline systemic 
inflammation or severity of illness has not been fully explored in patients with sepsis. 
Excessive inflammation has harmful effects and may be a contributing cause of HAI in 
the ICU.   
 
Sepsis is a complex disease involving a large number of genes. Several 
polymorphisms have been well characterized in sepsis.13-19  Knowledge is accumulating 
regarding the genetic susceptibility to infectious disease; however, gene-gene, gene-
environment, and host-pathogen interactions should also be considered.20-22  
Identification of promoter polymorphisms is important when examining an exaggerated 
inflammatory response. There are a number of important candidate polymorphisms that 
may be involved in the development of HAI. 
 
 
Specific Aims 
 
The purpose of this study is to determine the impact of baseline systemic 
inflammation (pro-inflammatory cytokine, anti-inflammatory cytokines, and their ratio), 
genetic variability, and environment on the development of HAI among patients with 
sepsis during their ICU stay.  One of the primary goals of this study is to determine 
whether exaggerated baseline systemic inflammation increases risk for development of 
2 
HAI during ICU stay. If true, this recognition may promote earlier detection and 
treatment of infections. Another goal of this study is to identify candidate genes involved 
in susceptibility of recurrent infections (new HAIs) in sepsis. It is unknown if these genes 
may differ from genes responsible for the sentinel sepsis event. 
 
 
The specific aims were to:  
 
1. Investigate whether baseline protein expression levels of pro-inflammatory 
cytokines, anti-inflammatory cytokines, or their ratios influence the development 
of subsequent HAI in patients with sepsis.  
 
2. Investigate the variance in cytokine genes to determine if they influence levels of 
protein expression or development of HAI.  
 
3. Investigate the effects of protein expression levels, genetic variation, and 
environment on development of HAI.  
 
 
Significance 
 
The findings of this study may provide important new insights into risk factors 
that contribute to the development of HAI in patients presenting to the ICU with sepsis. It 
is possible that these findings may be relevant for all patients who develop HAI, as 
patients may develop sepsis as the result of developing HAI. Targeting early exaggerated 
inflammation and increased severity of illness may allow earlier detection of HAIs, and 
promote earlier diagnosis and treatment, perhaps reducing the cost of care (by reducing 
hospital length of stay) and sequelae that lead to organ dysfunction and death. Thus, these 
findings may impact nursing and other critical care clinician practice first by helping to 
identify patients at risk, then implementing stricter targeted infection control practices in 
efforts to prevent development of HAIs (in addition to current standard and 
recommended practices), and lastly in early recognition and treatment when HAI occur. 
 
 
Conceptual Model  
 
The effects of sepsis and severe sepsis are far-reaching, with severe sepsis 
affecting approximately 751,000 annually in the US, with a 29-38% mortality rate.23 It is 
unclear how many of these cases represent new HAI (sepsis occurring at least three days 
after hospital admission) versus those who were admitted to the hospital or ICU with 
sepsis. Patients admitted with sepsis seem to be at higher risk for development of 
HAI.3,4,24  An appropriate immune response to an infectious insult 25 as well as early 
intervention of appropriate antibiotics, fluid resuscitation, and supportive care26-28 are key 
to a favorable outcome in sepsis.  Sepsis is the clinical manifestations of an infectious 
insult and was defined by Consensus Conference in 1992.29  These definitions are still 
commonly used by clinicians today, and their usefulness was reaffirmed by international 
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experts attending the 2001 International Sepsis Definitions Conference, who also 
proposed a new staging classification system using the acrostic PIRO (P=predisposition, 
I=insult infection, R=response, O=organ dysfunction), similar to the TMN approach used 
for tumor staging, to better characterize sepsis.30-34 Use of the PIRO model has been 
described as an effective classification system for researchers given the diversity and 
heterogeneity of patients with sepsis.35 Aspects of this system were incorporated into the 
conceptual model. 
 
The conceptual model for the development of HAI in sepsis (Figure 1-1) is very 
complex; yet, this map represents a simplified depiction and incorporates the work of 
others.4,31-33,35 The infectious insult, predisposing factors, severity of illness, and 
inflammatory response are all key factors to understanding the development of HAIs.   
 
 
Definition of Terms 
 
The following terms and definitions are provided for the major concepts in the 
model. These were the operational definitions used for this study.  
 
 
Elements of Sepsis  
 
• Systemic Inflammatory Response Syndrome (SIRS): The presence of at least 
two of the following: temperature > 38°C or < 36°C, minimum heart rate ( > 
90 per minute), elevated respiratory rate > 20 per minute) or a PaCO2 of < 32 
mmHg, and an abnormal white blood cell count ( >1 2,000 or < 4,000 cells 
μL−1) or bandemia ( > 10%).29 
 
• Sepsis: SIRS with an identified or suspected source of infection.29   
 
• Severe Sepsis:  The manifestation of sepsis with organ dysfunction.29   
 
• Sequential Organ Dysfunction Assessment (SOFA): The SOFA was used to 
assess the degree of organ failure among participants.  The SOFA score 
include assessment of six organs (Respiratory, Coagulation, Liver, 
Cardiovascular, Central nervous system, and Renal). The score for each organ 
ranges from 0 to 4, with a total SOFA score ranging from 0 to 24.36  
 
• Multiple Organ Dysfunction Score (MODS): The MODS score is an 
alternative approach for assessing these 6 organs assessed by SOFA.37  For 
this study the MODS is used to measure of the number of organs with 
clinically significant organ dysfunction (range 0 to 6). Similar to the SOFA 
score, the MODS score also provides a range of categories based on organ 
function from normal to extreme dysfunction. The cutoff for moderate 
dysfunction is considered to be clinically significant organ dysfunction. One 
point is assigned for each clinically significant organ dysfunction  using the  
4 
 
 
 
 
Figure 1-1.  Development of Health Care Associated Infections in Sepsis. 
 
  Note: This conceptual model incorporates the work of others.4,31-33,35 
 
  
  
 
Sepsis:  
Infectious insult 
plus systemic 
inflammatory 
response 
syndrome (SIRS) 
 
 
Predisposing Factor: 
Invasive Devices 
Genetic Predisposition 
Environmental Exposure 
Inflammatory 
Response 
Gene Expression 
 
Elevated 
Cytokines  HAI 
Severity of 
Illness: 
APACHE II  
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following criteria for each organ:  (A) Cardiovascular failure is defined by 
systolic blood pressure less than or equal to 90 mmHg which is not responsive 
to fluids; (B)  Pulmonary failure is defined by a PaO2:FiO2 of 300 mmHg or 
less; (C)  Central nervous system failure is defined as a Glascow Coma Score 
of 12 or less; (D) Coagulation failure is defined as a platelet count of 80,000 
or less; (E)  Renal failure is defined as a creatinine of 2 mg/dl or less; and (F) 
Hepatic failure is defined as a total bilirubin of 2 mg/dl or less.37 to fluids; (B)  
Pulmonary failure is defined by a PaO2:FiO2 of 300 mmHg or less; (C)  
Central nervous system failure is defined as a Glascow Coma Score of 12 or 
less; (D) Coagulation failure is defined as a platelet count of 80,000 or less; 
(E)  Renal failure is defined as a creatinine of 2 mg/dl or less; and (F) Hepatic 
failure is defined as a total bilirubin of 2 mg/dl or less.37 
 
• Infectious insult: Any definitive or suspected infection present at ICU 
admission will be described as a baseline infection. Suspected infections were 
defined clinically by the healthcare team.  
 
 
Elements of Severity of Illness   
 
• Severity of illness: An objective measure of each participant’s illness. 
 
• Acute Physiology and Chronic Health Evaluation II (APACHE II):  A 
commonly used severity of illness classification system designed to capture 
the worst of 12 physiological variables within the first 24 hours of ICU 
admission. APACHE II scores range from 0 to 71 with a higher scores 
associated with a worse outcome.38 APACHE II will be used as a measure of 
severity of illness in this study.  
 
 
Elements of Predisposing Factors 
 
• Predisposing factors:  Potential risk factors for development of HAI. 
 
• Invasive Devise: Any artificial device that bypasses the body’s first line of 
defense, the integument, is considered an invasive devise.  Common invasive 
devices in this study include endotracheal tubes, tracheostomy tubes, central 
venous catheters, peripheral venous catheters, arterial catheters, chest tubes, 
surgical drains, nasal and oral feeding tubes, percutaneous endoscopic 
gastrostomy tubes, and Foley catheters. 
 
• Genetic Predisposition: Increased susceptibility to a disease  due to the 
presence of one or more gene mutations, and/or a combination of alleles 
(haplotype), that are associated with an increased risk for the disease.39 In this 
study, single nucleotide polymorphisms (SNPs) will be used to detect genetic 
variation among participants. 
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• Single nucleotide polymorphisms (SNPs):  A difference in a single DNA 
nucleotide which can be measured and may be associated with disease.39 
 
• Environmental Exposure: Any potential exposure in a patient’s environment 
that could introduce an infection. In this study, environmental exposure 
includes invasive devices, nurse-patient ratios > 2:1, and administration of 
blood products. Universal precautions are expected to be followed on all 
subjects and this includes appropriate hand-washing, protective equipment 
use, and aseptic technique to prevent cross-infections.  
 
 
Elements of Inflammatory Response 
 
• Gene Expression: The process of translating genes into a functional protein 
product. For the purpose of this study, gene expression will be limited to 
measurement of cytokine proteins by multiplex bead based assays.  
 
• Cytokines:  Protein mediators of the inflammatory response.  
 
 
Health Care Associated Infections 
 
• Health care associated infection refers to any infection that occurs after at 
least three days of hospitalization which is not a recurrence of the baseline 
infection.  
 
• Specific HAIs are defined by CDC guidelines as described in the methods 
section. The operational definition for this study will include NEW HAIs that 
occur after at least three days of admission to the ICU which are not a 
recurrence of the baseline ICU infection. 
 
• HAI that occur up to 48 hours after ICU admission are considered to be ICU 
related HAI. 
 
 
Assumptions 
 
The following assumptions were made for the purpose of the study: 
 
1. An underlying assumption of this study is that baseline systemic inflammation 
will be prolonged. 
2. HAI will be detected when they occur.  
3. Subjects will be classified correctly in analyses based on degree of baseline 
systemic inflammation and development of HAI.  
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Potential Limitations 
 
This study included the following potential limitations: 
 
1. The usage of corticosteroid therapy may impact the degree and duration of 
systemic inflammation; thus, potentially limiting the possible impact of systemic 
inflammation on the development of HAI in participants receiving corticosteroids.  
 
2. The use of corticosteroids may limit fever among participants experiencing HAI, 
and may result in failure to detect HAI when they occur. It is recommended 
clinical practice in our ICU to use sepsis surveillance, and thus a high degree of 
suspicion when steroids are used. 
 
3. There may be predisposing factors for development of HAI that were not 
measured. 
 
4. Participants receiving mechanical ventilation may have lower DNA yields from 
buccal swabs due to the presence of a large obtrusive bite block which limited 
access to swab the inside of the entire cheek as recommended.  
 
5. The investigator is a novice bench researcher, and although efforts were made to 
accurately follow protocols, it is possible that errors could have influenced results.  
 
6. Endpoint genotyping of the single nucleotide polymorphisms RS1800896 
required manual calls in seven samples. 
 
7. Interleukin 6 was selected as a proinflammatory cytokine; however, it does have 
some anti-inflammatory properties. 
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CHAPTER 2.  BACKGROUND 
 
 
Background and Significance 
 
Health care associated infections (HAI) affect more than 2 million persons 
annually in the US, with approximately 35% occurring in the ICU. A 1999 Institute of 
Medicine report attributed 44,000-98,000 annual deaths and the associated cost was as 
high as $29 billion.40  HAIs (or hospital acquired infections) are typically referred to as 
infections that are not present or incubating at the time of hospital admission. Infections 
are “considered to be hospital-acquired if they develop at least 48 [hours] after hospital 
admission without proven prior incubation.”40 Common HAI’s in the ICU are 
bloodstream infection, pneumonia, and urinary tract infections.  Despite standard 
practices to prevent them, HAIs remain a significant public health care concern. 
 
 
HAI Incidence and Infection Patterns    
Rates of infections vary but the most common hospital infections in descending 
order are urinary tract infection, surgical wound infection, lower respiratory tract 
infection, bacteremia, and others.41 Infections are generally classified as primary or 
secondary and the source may be endogenous or exogenous.41 The National Nosocomial 
Infections Surveillance (NNIS) System collects surveillance information across medical 
intensive care units in the United States.  An analysis of NNIS data (n = 181,993) 
determined the most frequent types of HAI in the ICU were urinary tract infections 
(31%), pneumonia (27%), and primary bloodstream infection (19%) from surveillance 
data between 1992 and 1997.42  The most common pathogens reported were Coagulate-
negative Staphylococcus, Staphylococcus aureus, and Enterococcus spp. The authors 
provide a comprehensive summary with percentages for each type of infection. 
In contrast to the pattern of infections among all US ICU patients, a one day ICU 
prevalence study conducted in 1992 provides a similar pattern of infection types 
occurring in European ICU patients. In descending order, Vincent et al. reported the most 
common ICU infection as pneumonia (46.9%), lower respiratory tract infection (17.8%), 
UTI (17.6%), and bacteremia (12%) in a large European study of 10,038 subjects in 
1,417 intensive care units with a total of 4051 infections.43 These authors reported the 
most common organism as Enterobacteriaceae (34.4%) followed by Staphylococcus 
aureus (30.1%), Pseudomonas aeruginosa (28.7%), Coagulate-negative Staphylococci 
(19.1%), and fungi (17.1%). Organisms were not reported for each type of infection 
separately.43   
 
In a more recent study of a combined medical and surgical ICU, the most frequent 
infections (in descending order) were ventilator associated pneumonia, surgical site 
infection, lower respiratory tract infection, intrabdominal infection, sinusitis, soft tissue 
or skin infection, bacteremia, and finally, UTI.2  This study examined risk factors for 
mortality and organisms were not provided. The pattern of infections in the ICU varies. 
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The rates of NI may vary widely depending on the type of ICU and population served. 
Eggiman and Pitet provide a comprehensive list of infection rates by type of ICU.40 The 
causative organism may not be detected in all infections and the rate of viral infections in 
the ICU may be underappreciated. There is evidence that despite causative organism type 
(gram negative, gram positive, polymicrobial, or fungal) the host’s inflammatory and 
coagulation response is similar in severe sepsis.12    
 
 
Antimicrobial Resistance  
 
Several factors in the ICU contribute to promoting antimicrobial resistance. These 
include (1) cross-transmission often caused by the urgency of care that may result in 
inconsistent aseptic technique or hand washing, (2) compromise of host defenses through 
the use of invasive devices  which may become colonized, (3) the use of antibiotics.44 
The emergence of antibiotic resistant organisms such as Methicillin resistant 
Staphylococcus aureus (MRSA), Vancomycin resistant Enterococcus, and other 
multidrug resistant organisms are major concerns.44-47 Caution in antibiotic prescribing in 
both the community and hospital setting has been advised.    Only approximately 30% of 
antimicrobials used in hospitals are being given as definitive therapy for known infection 
associated pathogens based on microbiologic susceptibility.44  Cycling empiric 
antimicrobial therapy has been proposed to reduce antimicrobial resistance and has had 
favorable results in the susceptibility profile of gram positive but not gram negative 
organisms.48,49    
 
The concept of antibiotic cycling to reduce antimicrobial resistance has been 
around since at least 1986.50 Since microorganisms are generally adaptive to their 
environment, limiting the introduction of particular antimicrobial for periods of time may 
help to decrease resistance patterns. There are few controlled trials published. A number 
of methods have been proposed to assist with cycling including the use of hospital 
formularies.51  The use of local antibiograms should be used to guide empiric therapy and 
antimicrobial therapy should be guided by susceptibility testing as soon possible since a 
delay in appropriate antimicrobial therapy worsens outcome.  Antibiograms are 
frequently used to adjust antibiotics in the ICU; however, failure to use them in other 
settings is a contributor to antimicrobial resistance.52 
   
 
Risk Factors for Developing HAI  
 
Patients admitted to the ICU have an increased risk for developing HAI which 
may be related to underlying disease conditions, impaired immunity, invasive devices, 
inappropriate aseptic technique, or secondary infections after broad spectrum antibiotics.2  
Eggimann identifies severity of illness, prolonged length of stay, and vascular access as 
independent risk factors for the development of HAI. He provides a thorough review of 
infection control practices in the ICU, and attributes most infections to inadequate 
infection control practice, and also implicates understaffing and overcrowding of the ICU 
as contributing factors.40 Genetic susceptibilities are known to increase the risk of 
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developing infections;20,21 however, the influence of these genetic susceptibilities on 
development of subsequent HAI is unknown. Recommendations for standard practices to 
prevent the development of HAIs in the ICU have been reported by the Infectious 
Disease Society of America (IDSA), the Center for Disease Control (CDC), and  
others.53-57   
 
 
Role of the ICU Environment and HAI 
 
As noted in the prior sections, being a patient in the ICU presents several inherent 
risks factors for the development of HAI including: presence of invasive devices, use of 
broad spectrum antibiotics, use of blood products, and generally more physical contact 
with the health care team administering care.  A standard patient to nurse ratio for most 
critical care units is 2:1 depending upon patient acuity.  The implementation of open 
visitation in the ICU has the potential to introduce additional risk of cross-contamination 
to this vulnerable population.   Appropriate hand hygiene is essential to prevent cross-
contamination, in addition the CDC reports the potential role of HAI transmission by 
health care provides wearing rings and long or artificial nails.58  Routine isolation 
practices are used when any multi-drug resistant organism is detected.59 The floors are 
mopped and cleaned daily as well as between patients according to CDC guidelines.60   
The areas closest to the patient including the bed side rails, bed controls, bedside tray, 
and call light are typically only cleaned between patients unless soiled and may represent 
items that needs to be targeted for more frequent cleaning. 
 
 
Severity of Illness 
 
Severity of illness can be quantified by using the Acute Physiology and Chronic 
Health Evaluation (APACHE) II, a composite score that ranks a patient’s worst 
physiologic functioning within the first 24 hours of ICU admission.38  The APACHE II is 
in the public domain and was used for this study. Severity of illness has been investigated 
as a risk factor for developing HAI. Girou et al, conducted a retrospective case-control 
study (n = 82) with 1:1 matching based on initial severity of illness using APACHE II 
and also obtained serial APACHE II scores to determine the influence of severity of 
illness on development of infections.  Among several variables assessed, they identified 
day three APACHE II score as significantly higher in the cases (p = 0.04).61 All patients 
had similar APACHE II scores at baseline, and worsening of APACHE II score provides 
evidence of worsening severity of illness among those who developed HAI. In contrast, 
Vincent et al, in a one day prevalence study across 17 European ICUs (n = 10,038), 
identified a high APACHE II score of greater than 31 to be independently associated with 
risk of mortality; however, they reported the highest HAI rates in patients with APACHE 
II scores ranging from 11-20.43  
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Invasive Devices 
 
Invasive devices bypass the body’s first line of defense, the integument, and may 
lead to infection if penetrating organisms are not promptly sequestered by the innate 
immune system.25 Common invasive devices in the ICU include endotracheal tubes, 
central venous catheters, peripheral venous catheters, arterial catheters, chest tubes, nasal 
feeding tubes, and Foley catheters. Several studies have been published describing the 
relationship between invasive devices and infections.8,40,42,53,62-64  In many cases HAIs  
are used as a benchmark for quality of care, and Maki suggests that peripheral 
intravenous catheters (previously considered low risk) should begin to be targeted by 
infection control practices to reduce invasive device related infections.64 The use of 
antibiotic impregnated devices and targeted strategies have helped to reduce the rates of 
invasive devise related infections.65,66  
 
Invasive devices may be colonized with bacteria or fungi through biofilm 
formation. Biofilms generally forms when microorganisms adhere to invasive devices 
which provide them with an environment capable of evading antibiotics. They initially 
adhere to the foreign surface and then begin to secrete extracellular polymeric substance 
(EPS) to protect formation of the biofilm and attract other organisms. The 
microorganisms within a biofilm exhibit different physiologic and growth characteristics 
than do free floating (or planktonic) organisms.67 They use quorum sensing to 
communicate and control the gene expression of other organisms within the biofilm, and 
to control each phase of biofilm formation:  attachment, cell-to-cell aggregation, 
proliferation, EPS production, grown, and detachment or degradation.68 Acute infections 
are generally caused by the planktonic (free floating micro-organisms) but the role of 
biofilm formation on chronic and acute infection is an area of research.67,69,70 
 
 
Systemic Inflammatory Response Syndrome 
 
The body is subject to a variety of insults daily and the immune system is usually 
able to isolate and clear potential pathogens without systemic effects. When the body is 
not able to maintain inflammation at the local level, inflammation becomes systemic. The 
systemic inflammatory response syndrome (SIRS) is the clinical manifestation of the 
body’s host defense response to a variety of insults and initially manifests in at least two 
of four major organ systems (cardiovascular, hematopoietic, neurologic, and respiratory 
system).  These insults can be infectious or noninfectious in nature. Noninfectious insults 
include pancreatitis, burns, trauma, tissue ischemia or necrosis, massive transfusion, 
chemical aspiration, foreign bodies, and immune hypersensitivity reactions.29,71,72   
 
The goal of the inflammatory response is to control the initial insult or injury. 
Three primary responses (vascular, neutrophil, and plasma protein) function to increase 
blood flow to the affected area, increase vascular permeability to allow leukocytes and 
plasma proteins into the site of injury or infection.71  SIRS is a dysregulated 
inflammatory response caused by activation of inflammatory cells.  It is a generalized 
response regardless of the type of insult. This dysregulated inflammatory response leads 
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to generalized systemic inflammation, damaged vascular endothelium, altered immune 
function, fluid shifts, and organ hypoperfusion.71 If this process is not controlled, it can 
progress to multiple organ dysfunction syndrome.71  SIRS occurs in approximately one 
third of all hospitalized patients and one half of ICU patients.71    
 
 
Cytokines 
 
Cytokines are produced by a variety of cells (lymphocytes, macrophages, 
epithelium, endothelium, connective tissue, adopocytes, and myocytes) which modulate 
the function of other cell types.72 Cytokines are pleotropic which means that one cytokine 
can act on a number of cell types and have many effects.73 They have autocrine, 
paracrine, and endocrine effects. Cytokines play a role in both acute and chronic 
infections.72  Activated lymphocytes and macrophages are their primary secretor.  
Cytokines are not stored in their active states in the cell. Their production requires new 
mRNA and protein synthesis. Most are encoded as pro-peptides, transported to the Golgi 
body for glycosylation, and secretion as smaller mature cytokine proteins.74  
 
 A growing number of cytokines are still being discovered.  Interleukins mediate 
communication between leukocytes.   IL-1β  and TNF-α promote the acute inflammatory 
response, thus they are typically referred to as pro-inflammatory cytokines. IL-6 is 
another potent inducer of the acute inflammatory response. It stimulates the liver to 
release acute phase proteins. Although IL-6 is often referred to in the literature as a pro-
inflammatory cytokine, evidence is accumulating regarding its’ anti-inflammatory 
properties. IL-6 inhibiting effects of IL-1β  and TNF-α.75  IL1-ra and IL-10 are both 
know as anti-inflammatory cytokines. Table 2-1 summarizes the function of well known 
pro- and anti-inflammatory cytokines.  
 
 
HAI Risk Posed by the Inflammatory Response 
 
There is some evidence that cytokines may enhance extracellar and intracellular 
growth of bacteria76-79 and that anti-inflammatory cytokines may promote the 
development of infections.11,80   Kanangat et al. found, in an in vitro model, that 
monocytes that were primed with higher levels of proinflammatory cytokines 
experienced higher levels of intracellular bacterial growth; whereas monocytes primed 
with lower levels of proinflammatory cytokines experienced lower levels of intracellular 
bacterial growth.77 In another in-vitro study, Kanangat also found that cytokines 
enhanced the extracellular growth of Staphylococcus aureus.76 Because of the complexity 
of the inflammatory response which includes redundancy of the inflammatory networks, 
competing feedback loops, and simultaneous amplification pathways35, it is uncertain that 
a relationship that exists in-vitro will exist in-vivo.  
 
It is possible that high levels of cytokines function as bacterial growth factors76-79 
or that anti-inflammatory cytokines may promote the development of infections.11,80 It is 
also possible that an exaggerated inflammatory response may promote HIAs by inhibition  
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Table 2-1.  Summary of Cytokine Function. 
 
Cyokine  Function Reference 
IL-1β 
Mediate innate immunity. T cell activation. 
Macrophage activation. Fever. Induces production of 
IL-6. Induce endothelial adhesion molecules. 
25,73,81 
TNF-α 
Mediate innate immunity. Local inflammation. 
Induces acute inflammation by activation of and 
endothelial cells. Induce endothelial adhesion 
molecules. Activates macrophages and inducted 
nitric oxide production. Fever. Mobilization of 
metabolites. Shock.  
25,73,81 
IL-6 
Mediate innate immunity. Acute phase protein 
production. Fever. T and B cell growth and 
differentiation. Activates T and B cells. Down-
regulates the synthesis of IL-1 and TNF. 
25,73,75,82 
IL-10 
Potent suppressor of macrophage functions by 
inhibiting cytokine release. Inhibits TH1 cells. Effects 
B cells to increase MHC class II. Down regulate the 
immune response. Deactivates monocyte/macrophage 
proinflammatory cytokine synthesis. 
25,73,75 
IL-1ra Inhibits IL-1 by binding to the receptor by competitive inhibition of the receptor IL-1 site.  
25,75 
 
Note:  IL denotes interleukin.  TNF denotes tumor necrosis factor.  IL1ra denotes IL-1 
receptor antagonist.  MHC denotes major histocompatability complex.  T cells are T 
lymphocytes that were derived from the thymus. B cells are B lymphocytes that were 
derives from bone marrow.  TH1 denotes a class of T helper cells. 
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of Toll-like receptors (TLRs)83 or by impairment of neutrophil function.84  Toll-like 
receptors are a family of proteins that act as pattern recognition receptors and enable cells 
to recognize pathogen-associated molecular patterns.  TLRs allows the innate immune 
system to immediately recognize highly conserved bacterial, viral, and fungal 
components.83,85  An evolutionary mechanism that evolved to protect the host from the 
harm of an overly responsive immune system, such as exaggerated IL-6 levels, is the 
inhibition of Toll-like receptor signaling by IL-1 receptor associated kinase-M.86 High 
IL-6 levels have also been reported in a small study (n = 21) of patients with HAIs who 
had impairment of neutrophil function resulting in impaired phagocytosis and bacterial 
killing.84  If the relationship of exaggerated or high IL-6 levels and development of HAIs 
is confirmed in this study, the underlying mechanism will require investigation. 
 
There have been no clinical studies to determine how cytokines influence 
bacterial growth in sepsis. However, in 1997, Headley et al. studied the effect of 
infections and the inflammatory response in ICU patients (n = 34) with Acute Respiratory 
Distress Syndrome (ARDS). They found that the outcome in ARDS was not related to the 
development of HAIs but that it was attributed to the magnitude and duration of the 
inflammatory response. It is unclear if they specifically tested the association of baseline 
level of inflammation and development of subsequent HAI. One important finding was 
that when a new HAI developed, it was not accompanied by an increase in levels of 
inflammatory proinflammatory cytokines.87 The same authors have reported in the past 
that persistent elevation of inflammatory cytokines was a poor predictor of outcome. The 
authors provided evidence that non-survivors have high levels of inflammatory cytokines 
at baseline which persisted for at least the first 10 days, whereas, survivors had a lower 
baseline level which decreased over the first 10 days.88  It is unknown how long this 
relationship persists since data were not shown beyond 10 days. A similar persistent 
elevation of the pro-inflammatory cytokine, IL-6, was recently reported in non-survivors 
with severe sepsis.89 The first week to 10 days may describe a more homogenous 
population of early infections; however, infections may also be described as early, 
middle, and late infections.90   The relationship of persistent systemic inflammatory, 
when defined clinically as systemic inflammatory response syndrome (SIRS) and not 
based on cytokine levels, has been shown to significantly increase the risk for developing 
HAI in a trauma population.90,91 
 
The relationship of severity of illness and health care associated infections has 
been described.10 McCluster et al. similarly report that patients who developed HAI had 
higher APACHE III scores than those who did not develop HAI but the relationship was 
not statistically significant.9  Kinasewitz et al. analyzed multiple biomarkers from the 
PROWESS data set (n = 1,690), a randomized controlled trial of recombinant human 
activated protein C in severe patients with sepsis. They found significant correlations in 
biomarkers relative to increasing levels of APACHE II. Of interest, median and 
interquartile ranges of IL-6 (pg/ml) were increased for all participants with an increase 
for each quartile of APACHE II (1st quartile: 289 (245 - 369), 2nd quartile: 384 (322 - 
489), 3rd quartile: 623 (494 - 829), 4th quartile: 1043 (809 - 1613), p < 0.001).  Their data 
for IL-10 (pg/ml) was inconclusive as 59% were below the detection limit: (1st quartile:  
≤ 10 (10 - 10), 2nd quartile: ≤ 10 (10 - 10), 3rd quartile: ≤ 10 (10 - 30), 4th quartile: ≤ 10 
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 (10 - 27), p =  0.001).12  The APACHE II ranges for each quartile were: 1st quartile (3  
- 19), 2nd quartile (20 - 24), 3rd quartile (25 - 29), and 4th quartile (30 - 59). Criteria for the 
original study included severe sepsis with at least three signs of systemic inflammation 
and at least one organ failure.92 
 
It is assumed that patients with sepsis who present with a high degree of baseline 
systemic inflammation will have persistent inflammation which may contribute to the 
development of HAI.  The role of pro- versus anti-inflammatory cytokines in the 
development of sepsis is an area of debate. Assessment of the cytokine profile may be 
more predictive than assessing individual cytokines in isolation.93  Although other more 
common mechanisms for the development of HAI exist, such as poor aseptic techniques, 
the relationship of systemic inflammation and development of HAI in patients with sepsis 
presents a novel approach which is explored in this dissertation.  
 
 
Rationale for Selecting IL-6 and IL-10 
 
When planning this dissertation study, it was to be limited it to one pro-
inflammatory cytokine, one anti-inflammatory cytokine, and one ratio. Before this project 
began, there was concerned about the use of IL-1β and IL-1ra due to reports of low 
detection limits in the literature. In addition to measuring IL-1β and IL-1ra, we also 
measured TNF-α, IL-6, and IL-10. IL-6 and IL-10 were included as an alternative pro- to 
anti- inflammatory ratio since they were less likely to be below detection limits and 
because there were other reports examining these ratios.94  A large number of cytokine 
values were below the detection limit for IL1B (66 or 84%) and IL1ra (50 or 64%) which 
indeed limited comparison of their ratios. These low detection limits also limited our 
ability to detect a difference in cytokine levels for the associated SNP.  It is probable that 
these very low concentrations (below the 3.2 pg/ml threshold used in this study) are 
biologically important, despite the fact that they cannot be precisely measured.  A total of 
5 (6.4%) IL-6 levels and 29 (37.2%) IL-10 levels were below the detection limit. 
 
Numerous articles throughout the literature include IL-1β, TNF-α, and IL-6 as 
pro-inflammatory cytokines; however, it should be noted that IL-6 also has many other 
functions.  IL-6 not only induces the acute phase response causing the liver to release 
CRP and other acute phase reactants, it is also involved in immunoglobulin switching 
necessary for acquired immunity.95,96 IL-6 may have a protective effect against 
development of septic shock;96 whereas, minute amounts of TNF- α and IL-1β are potent 
initiators of septic shock.81  IL-6 has been shown to consistently correlate with clinical 
severity of inflammation, autoimmune, and infectious disease; whereas, this relationship 
is not always clear with IL-1 and TNF.97 IL-6 levels have been used to predict fatal 
outcome in septic shock whereas this has not been shown with TNF levels.  Dinarello 
concludes that among patients with septic shock, IL-6 levels seems to “represent the net 
effect of biologically active IL-1 and TNF”.97 
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Sepsis Polymorphisms  
 
Sepsis is a complex disease involving a large number of genes.  Genes are 
composed of deoxyribonucleic acid (DNA) which is a polynucleotide chain made from 
sugar (2-deoxyribose) linked to phosphate backbone with protruding nucleotide bases.  
These bases are either purines (Adenine and Guanine) or pyrimidines (Cytosine and 
Thymine). A polymorphism is a common variation (greater than one percent) in the DNA 
sequence among individuals; whereas, a mutation has a frequency of less than one 
percent. A single nucleotide polymorphism is the substitution of one of the four 
nucleotide bases with another nucleotide base and may confer a survival advantage.98 
Another type of polymorphism is a tandem repeat or microsatellite polymorphism, in 
which a number of nucleotides are repeated once or several times.  The normal or usual 
genotype is referred to as the wild type, although wild type can refer to the genotype or 
phenotype.99  
 
Only about 10 percent of the DNA sequence in the human genome codes for 
genes, and SNPs occur approximately every 1,000 base pairs with most not resulting in a 
protein or secretion change.98  SNPs occurring in the promoter regions of genes have 
potential to influence the level of gene expression and are likely to be important.  Several 
polymorphisms have been well characterized in sepsis.13-19  Knowledge is accumulating 
regarding the genetic susceptibility to infectious disease; however, gene-gene, gene-
environment, and host-pathogen interactions should also be considered.20-22   
 
Identification of promoter polymorphisms is important when examining an 
exaggerated inflammatory response. There are a number of important candidate 
polymorphisms that may be involved in the development of HAIs. Table 2-2 includes a 
brief review of selected polymorphism. Although evidence supports the importance of 
these polymorphisms in sepsis, a study of young, healthy white males with no smoking or 
co-morbidity history, found a trend but no clear association between common 
polymorphisms and cytokine levels in a sepsis model of endotoxin exposure.100 There is 
research indicating that epigenetic factors may down regulation genes as early as 3-5 
hours after an infectious insult which could be the reason the investigators did not find an 
association.101 It is reasonable to conclude that patients who have already shown 
susceptibility to sepsis by presentation to the ICU with sepsis have a different risk profile 
than these healthy young men. Additionally, polymorphisms in one cytokine gene may 
enhance expression levels of other cytokine genes.102  
 
 
Cytokine Gene SNPs for IL-6 and IL-10  
 
The gene for IL-6 is located on chromosome seven on the p arm. The gene for IL-
6 consists of 4,856 nucleotides and begins at location 22,766,766. The promoter region 
lies upstream from the gene. It generally starts approximately 25 bp upstream from the 
gene starting point but transcription factors have a large “footprint” and their binding to 
the promoter is necessary prior to the binding of RNA polymerase II and ultimate 
transcription of IL-6 into mRNA.103 There are several SNPs located within the promoter   
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Table 2-2.  Selected Cytokine Polymorphism Investigated in Sepsis. 
 
Cytokine  
Gene 
Location Polymorphism RS Number  Rationale Reference 
IL-1β 2q14 -511C/T rs1143643 
Mixed results. 
Increased risk for 
septic shock 
(C/T). 
104-106 
TNF-α 6p21.3 - 308 G/A rs1800629  A, increased risk for sepsis 
19,107 
IL-6 7p21 -174 G/C rs1800795  
G, higher 
cytokine levels, 
others lower 
levels 
16,18,108 
IL-10 1q31-q32 -1082 G/A  rs1800896  
G, shock, more 
severe sepsis, 
more severe 
pneumonia 
16,19,107 
IL-1ra 2q14.2 86-bp repeat na   A2, increased risk for sepsis 
16,18,19 
 
Note:  IL denotes Interleukin.  TNF denotes tumor necrosis factor.  IL1ra denotes IL-1 
receptor antagonist. 
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region of IL-6. RS1800795, previously known as -174G/C, is located at 22,766,645 and 
has been well described in the literature. It has been associated with both higher and 
lower levels of IL-6 when position RS1800795 is encoded by G.16,18,108  
 
The gene for IL-10 is located on chromosome one on the q arm. The gene for IL-
10 consists of 4891 nucleotides and extends from location 206,945,839 to 206,940,948. 
The promoter for IL-10 lies upstream from the gene and SNP RS1800896, previously 
known as -1082 G/A, is located upstream within the promoter region at 206,946,897.  It 
has been shown that the presence of a G at this position is associated with shock, more 
severe sepsis, and more severe pneumonia.16,19,107 
 
Figure 2-1 shows the location of these SNP upstream from the gene using the 
National Center for Biotechnology Information’s (NCBI) new Sequence Viewer v.2.12.  
 
 
HapMap Data for Genotypes 
 
The International HapMap Project began in 2002 with the goal of providing 
patterns of human DNA sequence variation to enable scientists to investigate genes 
affecting health, disease, and response to drugs and environmental factors. The 
HapMap Project is currently in its third phase, HapMap 3, which includes 1,301 
samples from eleven human populations, and 270 of those samples originating from 
prior phases.109  HapMap 3 included samples from African ancestry in Southwest USA 
(ASW) and Utah residents with Northern and Western European ancestry (CEU) were 
included. Tables 2-3 and 2-4 show the distribution. Note the difference between ASW 
and Africans from Sub-Sahara. Courtesy: National Human Genome Research Institute. 
 
 
Selection of Exclusion Criteria 
 
This study was designed to examine systemic inflammation and its influence on 
the development of HAI. Patients with a disease process know to decrease immune 
function and those receiving certain immunosuppressants could confound findings on 
HAI.  This includes patients with cancer and human immunodeficiency syndrome. It also 
includes patients on high dose corticosteroids or chemotherapy.  Acute phase proteins are 
secreted by the liver in response to inflammation; thus, patients with a liver failure (Child 
Pugh Score of C or worse) were also excluded. While the elderly may be more 
susceptible to infections due to a functional decline in cell-mediated immunity,110 we 
opted not to exclude patients based on age so that this relationship could be examined if it 
existed in this population. 
 
 
Preliminary Studies 
 
Until recently, there had been no clinical studies examining the relationship of 
excessive baseline inflammation with the development of subsequent health care  
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A. 
 
B. 
 
  
 
Figure 2-1.  Promoter SNP Locations. 
 Note:  The red down facing arrow in each image denotes the SNP location.  Image A 
shows the IL-6 gene and the location of rs1800795.  Image B shows the IL-10 gene and 
the location of rs1800896.  Images obtained from NCBI’s new Sequence Viewer v.2.12.  
Available from: http://www.ncbi.nlm.nih.gov/SNP/. 
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Table 2-3.  HapMap 3 RS1800795 Genotype and Allele Frequencies. 
 
Population Number CC CG GG 
CEU 226 0.319 0.434 0.248 
ASW 98 0 0.184 0.816 
YRI 120 0 0 1.0 
 
Note:  The ancestral allele is G.  CEU represents Utah residents with Northern and 
Western European ancestry.  ASW represents African ancestry from Southwest USA. 
YRI represents Africans from Sub-Sahara.  Courtesy: National Human Genome 
Research Institute. 
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Table 2-4.  HapMap 3 RS1900896 Genotype and Allele Frequencies. 
 
Population Number AA AG GG 
CEU 226 0.212 0.513 0.274 
ASW 98 0.449 0.429 0.122 
YRI 120 0.531 0.389 0.080 
 
Note: The ancestral allele is A.  CEU represents Utah residents with Northern and 
Western European ancestry.  ASW represents African ancestry from Southwest USA. 
YRI represents Africans from Sub-Sahara.  Courtesy: National Human Genome 
Research Institute. 
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associated infections. The investigator performed a retrospective 6 week feasibility study 
in the ICU where this dissertation study subsequently occurred.24 Since cytokine 
measurements were not clinically available, the relationship of baseline C-reactive 
protein (CRP) to the development of HAI was examined. All patients admitted to the 
MICU/CICU for 6 weeks beginning 1/1/08 were screened for inclusion. All subjects with 
a CRP drawn within 24 hours of ICU admission were included. Baseline demographics, 
CRP, diagnoses, SIRS, APACHE II, MODS, infections, and invasive devices were 
recorded and all patient records were reviewed through ICU discharge for the 
development of HAI. Comparisons were made among those who did and did not develop 
HAI. 
 
Among 69 patients admitted to the ICU during the study period, 27 patients had 
CRP levels within the first 24 hours. Among the 27 patients included in this older (62.3  
± 12.9), male (96.3%) heterogeneous population, the mean APACHE II score was 17.8   
± 7.0; 25.9% required vasopressors, 59.6% had suspected or definitive baseline 
infections, 40.7% required mechanical ventilation, and the median baseline CRP level 
was 58.4 mg/dL with wide variation (range 3 - 548). Nine (33.3%) patients developed 
HAI (total of 15 infections) with bacteremia and UTI being most common. There were no 
significant differences in survival, baseline CRP, APACHE II , SIRS, MODS, or hospital 
length of stay in those who did and did not develop NI. There was a trend (p = 0.10) 
towards development of a difference in ICU length of stay (10.4 vs. 4.4) in those who 
developed new HAI versus those who did not, respectively. Patients with baseline 
infections were more likely to develop new HAI 8 (88.9%) compared to those who did 
not present with an infection 1(11.1%), p = 0.04. Although this was a small sample, it 
suggests increased susceptibility to new HAI in those who were admitted with sepsis. 
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CHAPTER 3.  METHODS 
 
 
Research Design  
 
This study was designed as a prospective observational study to evaluate the 
effects of baseline systemic inflammation as measured by cytokine levels on the 
development of HAIs in patients admitted to the ICU with sepsis or suspected sepsis. 
Baseline pro-inflammatory cytokine, anti-inflammatory cytokine, and their ratios, along 
with a common single nucleotide polymorphism for each cytokine tested were examined 
among patients with sepsis who did and did not develop subsequent HAIs. Approval for 
human subject’s research was obtained from the Memphis-Veteran’s Affairs Medical 
Center (VAMC) Institutional Review Board (IRB) and University of Tennessee Health 
Science Center (UTHSC) IRB, as well as the VAMC’s Research and Development 
committee.  
 
 
Study Population 
 
All patients admitted to the Veterans Affairs Medical Center’s Medical Intensive 
Care Unit (MICU) were systematically screened for sepsis at admission.  A sample size 
of 78 subjects was required to detect a 30% difference (40% in those with high systemic 
inflammation versus 10% in those with low systemic inflammation) in development of at 
least one HAI during ICU stay (up to ICU day 28).  This calculation was estimated for 
patients with high baseline levels of systemic inflammation (pro-inflammatory cytokine 
level within 4th quartile) versus patients without high levels of systemic inflammation 
(pro-inflammatory cytokine level not within 4th quartile) with an 80% power given a 3:1 
ratio.   
 
 
Inclusion Criteria 
 
The following two conditions were inclusion criteria: 
 
1. Presence of Sepsis within 72 hours of admission to the ICU:  Sepsis is defined 
as systemic inflammatory response syndrome (SIRS) plus an identified or 
suspected infection. SIRS is defined as at least two of the following: abnormal 
temperature ( > 38°C or < 36°C), minimum heart rate ( > 90 per minute), 
elevated respiratory rate ( > 20 per minute) or a PaCO2 of < 32 mmHg, and an 
abnormal white blood cell count ( > 12,000 or < 4,000 cells μL−1) or bands > 
10%.   
2. Age 18 or older. 
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Exclusion Criteria 
 
The following four conditions were exclusion criteria:  
 
1. Receiving Immunosuppressive agents such as chemotherapy or greater than 1 
mg/kg of prednisone or equivalent dose within the past 3 months. 
2. Other Immunosuppression: AIDS. 
3. Liver Failure defined as Child Pugh category C or higher. 
4. Lack of informed consent. 
 
 
Procedures 
 
This section includes study related procedures. 
 
 
Summary of Procedures  
 
A summary of all study procedures over time is included in Table 3-1. Procedures 
included screening, informed consent, data collection, specimen collection, and specimen 
analysis. 
 
 
Screening 
 
Efforts were made to screen all patients for inclusion and exclusion criteria who 
were admitted to the medical intensive care unit (MICU). Rounds were systematically 
made in the MICU and the principle investigator interacted with the MICU medial team, 
nursing staff, and reviewed records to determine if patients met eligibility. A waiver of 
informed consent was obtained from the IRB to allow for screening of patient records for 
eligibility. Patient records included their electronic chart, nursing flowsheets, x-ray films, 
and other pertinent reports needed to determine eligibility. The principle investigator 
completed training in human subject’s protection prior to initiation of this research.    
 
 
Informed Consent 
 
Subjects who met inclusion criteria and had no exclusion criteria were approached 
for informed consent. When subjects were too ill to provide their own informed consent, 
then a legally authorized representative/surrogate decision maker was sought for informed 
consent. All legally authorized representatives (LAR) who provided informed consent met 
requirement established by VAMC-IRB (see Appendix D, Informed Consent).  The LAR 
designation used for this study was adopted from Tennessee State Law; however, a new 
designation has recently been adopted based on the latest release of the Veteran’s Affairs 
Research Handbook which further limits LAR in regards to HIPPA consent for research.  
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Table 3-1.  Study Procedures. 
 
  Days 
Procedures 1 2 - 28 
ICU Discharge 
(or Day 28) 
Screening for inclusion/exclusion x   
Informed consent x   
Data collection    
Sepsis source and medical history x   
APACHE II x   
Health care associated infection x x x 
Invasive devices x x x 
Antibiotics, SIRS score, vital signs x x x 
Clinical and lab assessments x x x 
HAI preventive strategies x x x 
Adverse events x x x 
Plasma collection for cytokines x   
Buccal swab collection for DNA x   
Outcome assessment   x 
 
Note: ICU denotes intensive care unit. SIRS denotes systemic inflammatory response 
score. 
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As of March 2011, the only authorized LAR will include only individuals appointed 
under the Durable Power of Attorney for Health Care or a court-appointed guardian. 
 
 
Data Collection 
 
Baseline demographic variables were collected at ICU admission including age, 
race, and sex. Baseline sepsis (SIRS plus infectious cause) were collected in addition to 
descriptive variables surrounding baseline sepsis including the presence of organ failure 
(SOFA and MODS) and severity of illness (APACHE II).   
 
Several predisposing factors were collected. Baseline plasma IL-6 and IL-10 
levels were measured as well as their associated SNPS ra1800795 and rs1800896, 
respectively. Potential environmental exposures were also collected including invasive 
devices, nurse-patient ratios > 2:1 for any 4 hour period each day, and administration of 
blood products. The number and type of invasive device was recorded each day and the 
cumulative invasive devise score was recorded at the time of HAI and ICU discharge. 
Duration of ICU stay was collected.  
 
Patients were followed through their ICU stay (or up to 28 days) for the presence 
of HAI based on CDC guidelines. Descriptive variables surrounding the first HAI were 
recorded including SIRS and organ failure (SOFA and MODS).  
 
In addition to the primary variables a number of other variables were collected to 
better characterize the sample including vital signs, SIRS score, clinical triggers, all 
cultures, standard of care laboratory tests, standard of care CXRs, antibiotic use, use of 
steroids, and HAI preventive strategies.   
 
Data were collected by the principle investigator using standardized forms which 
were updated during the data collection process (see Appendix E). Information about 
adverse events (primarily deaths) occurring during the study period were collected and 
reported to the IRB. The occurrence of life threatening arrhythmias and respiratory and 
cardiac arrests were also recorded. Data collection after ICU discharge was limited to 48 
hours after ICU discharge for assessment of HAIs that could be attributed to ICU stay.    
 
 
Reliability and Validity of Common ICU Measures   
 
Vital signs are routinely recorded hourly in the ICU unless otherwise indicated. 
The values recorded by the critical care nurses during the course of standard patient care 
were reviewed. There was some variability in these measures and it was observed that 
respiratory rate was sometimes collected from the EKG respiratory lead (where it is 
captured and retained by the monitor) rather that from the ventilator display. There were 
instances of respiratory rates recorded that were lower than the ventilator set rate. When 
this occurred, the set ventilator rate was recorded as the minimum respiratory rate rather 
than the rate recorded on the flowsheet. Calculation of APACHE II requires the highest 
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or lowest values within the first 24 hours, along with the worst lab values in this time 
period.  The MICU uses bedside monitors with automated blood pressure cuffs which 
will provide for consistency in blood pressure readings.  Arterial lines and central lines 
were routinely calibrated and maintained by bedside nurse per hospital policy. Standard 
quality control procedures in the hospital’s laboratory include calibration of equipment at 
least every 8 hours and as needed. During the course of this study, Exergen’s Temporal 
Scanner TAT-5000 Temporal Artery Thermometer became routine use in the MICU.  
There were no pilot studies to test the reliability or consistency of this method and it may 
have introduced some bias in temperature measurement, and therefore SIRS scores.   
 
 
Data Entry 
 
Participant records were examined prior to data entry to assure that data 
collection was complete.  Clinical data were entered into a FilemakerPro® database.   
Prior to data analysis, data was exported to Excel, and all data was reviewed and cross 
checked for accuracy. Corrections were made to provide the most accurate dataset 
possible. Laboratory data (cytokine measures) were imported directly into Excel from the 
Luminex machine. Data from the LightCycler® 480 Instrument were also imported to 
Excel for data analysis.  Tests that did not meet specified conditions were repeated, and 
excel spreadsheets were updated to reflect additional results. 
 
 
Measurements 
 
This section provides detail for study measurements.  
 
 
Health Care Associated Infections 
 
A HAIs were defined as any infection occurring after day 3 through ICU 
discharge (or day 28 in participants with a prolonged ICU stay), excluding recurrent 
positive baseline infections.  All participants were monitored with equal diligence for the 
development of HAIs daily through ICU discharge (or day 28 in participants with a 
prolonged ICU stay). Participants who were discharged from the ICU prior to day 28 
were followed for 48 hours in the hospital. All infections that occur up to 48 hours after 
ICU discharge were also considered ICU related infections, just as infections occurring 
within 48 hours of hospital admission are considered community acquired. If a 
participant was readmitted to the ICU within 48 hours of ICU discharge, the patient was 
followed as though their ICU stay had been continuous.  
 
All culture results during the study period were recorded.  Developing an HAI 
during ICU stay was the primary outcome measure in this study. Each patient was 
classified as either having or not having a definitive HAI during ICU stay by culture 
criteria as defined below. Furthermore, the timing to development of first HAI was also 
recorded. The specific type of HAI and causative organism were recorded. Borderline 
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HAIs were adjudicated by pulmonary and critical care consultation.  HAIs  were recorded 
in such a manner to allow for future incidence density calculations.  The number and type 
of devices were recorded daily for each subject. 
 
This study was implemented using the most recent HAI definitions by CDC 
Guidelines at that time.111   In November 2008, new HAIs guidelines replaced existing 
guidelines.112  These new guidelines implemented minor changes in HAI definitions but 
required that the new term “heath care associated infections” replace the prior term 
“nosocomial infections”.  Additionally, the names of common HAI have been updated to 
reflect the new guidelines. The operational definition for each type of infection did not 
change. Health care associated infections were defined by CDC Guidelines111 as follows, 
and terms were revised to meet current guidelines:112  
 
• Bloodstream infection (formerly bacteremia) was defined by the presence of 
a microorganism cultured from blood which is not related to another site of 
infection. At least one blood culture is required to be positive, and when the 
identified organism is a potential skin contaminant such as coagulase-negative 
staphylococcus, two or more blood cultures must be positive.  
• Pneumonia was clinically defined as the presence of fever ( > 38◦C), 
leukopenia ( < 4,000 WBC/mm3) or leukocytosis ( > 12,000 WBC/mm3), and 
new or worsening infiltrate on CXR (or the presence of consolidation or 
cavitation), and at least two of the following: (1) new onset of purulent 
sputum, or change in sputum of change increased respiratory secretions, or 
increased suctioning requirement, (2) New onset of worsening cough, or 
dyspnea, or tachypnea, (3) Rales or bronchial breath sounds, or (4) worsening 
gas exchange, increased oxygen requirements, or increased ventilation 
demand.   Pneumonia was also definitively defined by positive bronchial 
alveolar lavage (BAL) with at least 104 cfu/ml. 
• Urinary tract infection (UTI) can be either symptomatic or asymptomatic. 
Symptomatic UTI is defined as a positive urine culture with > 105 
microorganisms/ml and one of the following: fever ( > 38◦C); frequency; 
dysuria, loin pain; loin/suprapubic tenderness. A culture count of  > 103 
microorgansims may be considered significant if obtained from a suprapubic 
puncture or in the presence of an antibiotic. It should be noted that many 
critical care patients may not be able to communicate their symptoms and 
steroids may results in failure to exhibit fever; therefore, culture counts of > 
105 microorgansims in a urine culture obtained from an indwelling Foley 
catheter were considered to be urinary tract infections.  Other infections of the 
urinary tract include presence of an abscess by direct observation during a 
surgical procedure. 
• Sinusitis was defined by organisms cultured from the sinus cavity with the 
presence of radiographic changes. In addition, one or more of the following 
symptoms with no other recognized cause may be present: fever (> 38◦C), 
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pain or tenderness over the involved sinus, headache, purulent exudate, or 
nasal obstruction.  
• A Cardiovascular system infection –VASC (formerly catheter-related 
infection) was defined as at least 15 colonies by semi-quatitative culture from 
an intravascular cannula tip in the presence of fever ( > 38◦C), pain, erythema, 
or heat at involved vascular size regardless of blood culture results. 
Additionally, a catheter related infection can be diagnosed if purulent drainage 
was present at the vascular site.   It should be noted that many critical care 
patients may not be able to communicate their symptoms and steroids may 
results in failure to exhibit fever.  
 
In addition to infections that are definitive (evidence by positive cultures), it is 
possible that a patient may have had an infection that is not detected by culture. All 
patients were followed prospectively.  In the absence of positive cultures, a high degree 
of clinical suspicion of infection which is treated and improves with an antibiotic was 
recorded. New fever in the ICU can be infectious or non-infectious, thus it is standard 
practice that any new fever is carefully investigated by the critical care team.54  All 
potentially non-definitive infections were reviewed with a critical care clinician. Primary 
analysis will include only definitive infections.    
 
 
Invasive Devices 
 
The presence of invasive devices was recorded daily through ICU discharge (or up 
to 28 days for participants with a prolonged ICU stay).  Invasive devices include 
endotracheal tubes, central venous catheters, peripheral intravenous catheters, arterial 
catheters, chest tubes, nasal feeding tubes, Foley catheters, and other drains or catheters 
that have been inserted.  A total daily invasive devise score as well as a cumulative daily 
score will be calculated for each patient. Each invasive devise will be given a score of 1. 
For example, if a patient has three invasive devices for days 1-5, then only one device for 
days 6-14, then their daily score will be 3 for the first five days and 1 for subsequent 
days. On day 14, the cumulative score will be (3*5 + 1*9) = 24.  A cumulative score for 
each day of the study will provide an estimate of their total exposure to invasive devices 
at any given time during the study period. This is a novel way to examine invasive 
devices and may be important since infections that occur early (day 5) will have less 
exposure to invasive devices than those that occur later. The invasive device score to be 
used in the regression model will be the invasive device score at the time of first HAI. In 
patients who do not develop any HAIs, the total ICU stay (up to day 28) invasive device 
score will be used in the regression model. 
 
 
Specimen Processing and Analysis 
 
Universal precautions were used during specimen collection, processing, and 
analysis. All specimens were collected at study entry.  
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Plasma Processing  
 
Blood was collected on each participant at baseline in 5 ml ACD tubes. The 
samples were placed on ice immediately and transported to the laboratory for processing 
as quickly as possible. A refrigerated centrifuge was used in the hospital Core Lab to spin 
the samples for 15 minutes at 2000G to separate the plasma from other blood 
components. Each plasma samples was then aliquoted into 2 equal portions and stored at 
-80 degrees until batch analysis. Samples were placed on dry ice when moving across 
campus prior to storage in the Crowe Building freezer, where all analyses were to be 
performed.   
 
 
Cytokine Analysis 
 
The cytokines for IL-6 and IL-10 were measured (pg/ml) in duplicate by Luminex 
(Luminex Corporation, Austin, TX) using Human Cytokine/ Chemokine Multiplex Kits 
(Millipore Corporation, Billerica, MA) according to manufactures instructions. In brief, 
previously frozen plasma samples were prepared by vortexing and certifuging to remove 
particulates before performing the assay. Beads were mixed according to instructions. A 
standard curve was prepared with the concentrations of 3.2 pg/ml, 16 pg/ml, 80pg/ml, 
400 pg/ml, 2000 pg/ml, and 10,000 pg/ml. The 96 well plate was prepared by adding 200 
μl of wash buffer to each well, shaking at room temperature for 10 minutes, and then 
vacuumed. Next, 25 μl of standard each curve concentration, each control, and assay 
buffer were added to each well in duplicate as indicated. The plasma samples were then 
added to the appropriate sample wells (25 μl) and serum matrix (25 μl) added to each 
standard curve and control well. Next, 25 μl of mixed beads were added to each well. The 
plate sealed and incubated overnight on the shaker at 4°C. The next day, fluid was 
removed by vacuum and the plate was washed twice with 200 μl of wash buffer and 
vacuumed. Next, 25 μl of detection antibodies were added and the plate was placed on 
the shaker for one hour at room temperature.  Next, 25 μl of Streptavidin-Phycoerythrin 
was added to each well. The plate was sealed and placed on the shaker at room 
temperature for 30 minutes. The plate was then vacummed and washed twice with 200 μl 
of wash buffer. The beads were then resuspended in 150 μl of sheath fluid and analyzed 
on the Luminex machine. 
 
Luminex software provides an automated data interpretation report with standard 
curves. It provide several report, including a bead count report, median florescent 
intensity (MIF), results, and average results for duplicates. Luminex software calculates 
the results by extrapolating MIF values on the standard curve.  No reading can be 
accurately measured if below the lowest point on the standard curve (3.2 pg/ml) or above 
the highest point on the curve (10,000 pg/ml).  When results occur outside of these 
detectable limits, the lowest or highest detectable value is substituted for statistical 
purposes. Results for each well were reviewed. According to the manufacturer 
instruction, data resulting from a cell with a bead count of at least 50 beads provides 
reliable results. In cases where the bead count was less than 50 or when the duplicate 
results were greater than 10 percent difference, the assay was repeated to increase the 
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accuracy of the measurement. A total of four were batches run. Batch one (samples 1       
- 39), batch two (samples 1 - 39), batch three samples 40 - 78), and batch four (repeat 
samples from batches two and three).    
 
It was initially anticipated that only two kits would be needed to complete these 
measurements and two kits were ordered. There were multiple issues with batch one due 
to wells not vacumming and low bead counts.  It was considered a test batch and none of 
the results were used. Two additional kits were ordered to assure that the same lot 
number was used, and the prior additional kit was retained to run repeat samples as 
needed. Batch 4 included duplicate samples from batch two and three that were needed to 
clarify the results as well as several additional duplicate samples to test reproducibility. 
Before the analysis was complete, the bead counts became extremely low and it was 
assumed that the Luminex needle was clogged. The system was flushed to assure that the 
needle was working properly. The plate was vacuumed and beads were resuspended with 
150 μl of sheath fluid, and the analysis for batch four was repeated. This time the bead 
counts for the first few wells (which previously had sufficient bead counts) were 
extremely low and the batch was discontinued.  Limited results from batch four were 
available. Results and bead counts were carefully reviewed. A total of five cytokines 
were actually tested but only two are included in this dissertation study. It was a puzzling 
finding that some wells (from batches 2 and 3) which had sufficient bead counts for one 
cytokine but not another could have different results when retested.  Each batch contained 
its own standard curve and controls. Perhaps this could be explained by the fact that the 
kit used for batch four had a different lot number and samples 1 - 39 had undergone one 
freeze thaw cycle. Most samples were measured in duplicate and averaged. Due to the 
inconsistent results of batch four, results from batch 2 and 3 were used primarily. A small 
number of values are based on single and not duplicate values.   
 
 
Reliability and Validity of Cytokine Measures  
 
The literature describes a high degree of variability among earlier generation 
cytokine results obtained from different manufacturers.  Studies from the early 1990’s 
found great variably in cytokine measurements depending on the type of fluid being 
analyzed and the assay used.113  Fahey et al. compared laboratories testing for cytokines 
and found both intra and inter laboratory variability. Several problems were identified 
before uniform results were obtained.114  The World Health Organization established 
cytokine standards to facilitate development of cytokine kits in research, and resulted in a 
dramatic reduction of the variation.115 It is recommended that when measuring cytokines, 
the same manufacturer’s kit, methods, and lot number are used to enhance the internal 
validity of the study. Millipore reports precision percentage for inter-assay is 3.7 - 17.2 
and intra-assay is 4.6 - 13.8.  
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Buccal Swab Collection for DNA 
 
The Catch-All™ Sample Collection Swabs from EPICENTRE Biotechnologies 
were used to collect buccal/cheek swabs. Specimens were collected by swabbing the 
inner aspect of the cheek and retaining the sample until ready for DNA extraction.  All 
specimens were collected without the presence of tea or coffee for at least one hour. 
Yield is directly correlated with the starting amount of buccal cells; therefore, swabs were 
collected in duplicate due to the concern of low yield among patients receiving 
mechanical ventilation in which access to the mouth is obscured by a large bite block.  
Specimens were allowed to dry at room temperature, returned to the collection sleeve, 
temporarily stored at room temperature, and then transferring to a -20 degree freezer in 
the Crowe building. The protocol allows for storage at room temperature for up to one 
week. Several specimens were stored in a locked cabinet for 24 to 48 hours prior to 
freezing. 
 
 
DNA Extraction  
 
The BuccalAmp™ Rapid DNA Extraction Kit was used to extract DNA 
according to the manufactures instructions and to prepare DNA for PCR amplification 
assays.  In brief, frozen buccal swabs were allowed to thaw at room temperature. Tubes 
containing Quick DNA Extraction Solution (stored at -20 degrees) was allowed to thaw 
at room temperature. One of these tubes was then labeled for each patient. The tip of each 
buccal swab was gently rotated 10 times in a tube containing Quick DNA Extraction 
Solution.  The swab was carefully removed while rotating and pressing on the side of the 
tube to prevent solution loss.  The top was secured tightly on each tube, and then the 
tubes were vortexed for 10 seconds, incubated at 65°C for 1 minute, vortexed for 15 
seconds, incubated at 98°C for 2 minutes, and then vortexed for 15 seconds. This process 
was done in batches as samples accumulated.  A random sample (n = 6) was tested by 
spectrophotometry to assure the presence of DNA by examining 260/280 ratios, and then 
samples were stored at -70 degrees until ready for genetic testing.  In the random sample 
5/6 samples contained DNA.  All samples were taken to the MRC to test the DNA 
quantity by NanoDrop but after checking several samples it was discovered that the 
proprietary reagents in the rapid extraction kits interfered with these results. According to 
manufactures instructions, SNP analysis can be performed without quantization or 
purification using this method. 
 
 
DNA Analysis 
 
SNP analysis was performed by real-time polymerase chain reaction (PCR) using 
the LightCycler® 480 Instrument, located in UTHSC’s Molecular Resource Center 
(MRC).  TaqMan® SNP Genotyping Assays, Human, SM (40X) for rs1800795 and 
rs1800896 from Applied Biosystems (Life Technologies, United States, 2006) contained 
florescent reporter tags (VIC and FAM) to determine alleles 1 and 2, respectively. Table 
3-2 includes SNP primer details.  A context sequence is given for proprietary primers.  
33 
Table 3-2.  SNP Primer and Reporter Details for Genotyping. 
 
Cytokine IL-6 IL-10 
RS number rs1800795 rs1800896 
Forward Primer CGACCTAAGCTGCACTTTTCC 
. 
Reverse Primer GGGCTGATTGGAAACCTTATT
AAGATTG 
. 
VIC Reporter 
Sequence 
CCTTTAGCAT[G]GCAAGAC . 
FAM Reporter 
Sequence 
CCTTTAGCAT[C]GCAAGAC . 
Context 
Sequence 
. TCCTCTTACCTATCCCT
ACTTCCCC[T/C]TCCCA
AAGAAGCCTTAGTAGT
GTTG 
VIC Reporter   Targets C Targets A 
FAM Reporter   Targets G Targets G 
X Allele GG GG 
Y Allele CC AA 
Both Alleles GC AG 
 
*  Roche LightCycler®480 Software reports describe alleles as Allele X, Allele Y, or 
Both Alleles.  Allele X binds to fluorescent probes FAM at 483-533 nm, Allele Y binds 
to fluorescent probes VIC/HEX/Yellow555 at 523-568 nm. 
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Roche LightCycler® 480 Probe Master Mix and PCR plates were obtained from the 
MRC.  A Master Mix was specifically made for each analysis which contained the 
Genotype Assay, Probe Master Mix, and PCR-grade water. The Genoype Assay was 
adjusted to a 20x concentration in the Master Mix.   The total volume of each Master Mix 
depended on the number of reactions.  The final reactions volume was 10 μl and 
contained 1 μl of unpurified DNA, 0.25 μl of the Genotype Assay, 5.0 μl TaqMan Master 
Mix, and 3.75 μl PCR-grade water. Real-time PCR was performed according to 
manufacturer’s instructions. Standard PCR methods were used. A negative control using 
PCR-grade water rather than DNA was included in each experiment.  PCR included one 
preincubation period (1 cycle at 95°C), incubation (45 cycles at 95°C, 62°,  and 72°C), 
and cooling period (1 cycle at 40°C). The primer target temperature is typically set 
approximately 5°C below the primer melting temperature (Tm); however, the Applied 
Biosystem’s TaqMan® SNP Genotyping Assays are all optimized for 60°C. If additional 
optimization is required, the manufacturer recommends either shortening cycle time to 40 
or increasing the temperature to 62°C.   
 
 
Statistical Analysis 
 
Data were analyzed with SAS (Version 9.1) using standard statistical techniques, 
including chi-square, student’s t-test, correlations, and Cox regression modeling. 
Univariate testing was performed on all continuous variables, and variables not normally 
distributed were either log transformed to achieve a normal distribution or non-
parametric tests were performed. Chi-square tests with expected cell counts less than five 
were analyzed using Fisher’s Exact test. An alpha level of 0.05 was considered 
statistically significant. Each aim includes pre-specified research questions and assumes 
complete data for the primary variables of interest. 
 
 
Aim 1 
 
This aim investigates whether baseline protein expression levels of pro-
inflammatory cytokines, anti-inflammatory cytokines, or their ratios influence the 
development of subsequent HAI in patients with sepsis.  
 
 Chi-square (χ2) tests were performed to test the proportions of patients with and 
without high systemic inflammation (4th quartile, IL-6 vs. other quartiles) who develop 
one or more HAI. χ2 tests were performed to test the proportions of patients with and 
without high systemic inflammation (4th quartile, IL-10 vs. other quartiles) who develop 
one or more HAI. The ratio of IL-6:IL-10 were calculated and each participant 
categorized based on their ratio. A ratio greater than 1 indicates a more prominent pro-
inflammatory response, a ratio less than one indicates a more prominent anti-
inflammatory response. Student’s t was performed to determine prominent inflammatory 
response among those who do and do not develop one or more HAI.  Mean cytokine 
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levels (IL-6, IL-10) and their ratio (IL-6:IL-10) will be compared using student’s t among 
participants who do and do not develop a HAI during their ICU stay. 
 
1.1  Does an exaggerated pro-inflammatory response influence subsequent 
HAI development in patients with sepsis?  
1.2  Does an exaggerated anti-inflammatory response influence subsequent 
HAI development in patients with sepsis?  
1.3   Do the ratios of pro-inflammatory and anti-inflammatory cytokines 
influence subsequent HAI development in patients with sepsis?  
1.4  Describe baseline cytokine patterns among patients with sepsis who do 
and do not develop subsequent HAI? 
 
 
Aim 2  
 
This aim investigates the variance in cytokine genes to determine if they 
influence levels of protein expression or development of HAI.   
 
ANOVAs were performed to determine the cytokine levels for each genotype. 
Chi-square analysis were also used to compare differences in common polymorphisms 
among those with exaggerated inflammation (4th quartile) at baseline as well as among 
those who do and do not develop HAIs.  
 
2.1  Is a particular IL-6 genotype associated with a higher level of IL-6? 
2.2  Is a particular IL-10 genotype associated with higher levels of IL-10? 
2.3  Is a particular IL-6 genotype associated with a higher rate of HAI 
development? 
2.4  Is a particular IL-10 genotype associated with a higher rate of HAI 
development? 
2.5  Is a particular haplotype associated with a higher rate of HAI 
development? 
 
 
Aim 3  
 
This aim investigates the effects of protein expression levels, genetic variation, 
and environment on development of HAI.  
 
A series of Cox regression analyses was performed among those who did and did 
not develop HAIs during ICU stay (or up to 28 days in those with a prolonged ICU stay) 
controlling for a number of potentially confounding variables including age, race, sex, 
severity of illness (APACHE II), baseline cytokines, ICU length of stay, invasive device 
score, steroid use, and potential confounders. Questions 3.1-3.7 were answered by 
univariate testing. Questions 3.8 and 3.9 were answered by multivariate testing. 
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3.1. What is the risk ratio to predict development of HAI for each 10 point 
increase in APACHE II?  
3.2. What is the risk ratio to predict development of HAI for each additional 
invasive devise?  
3.3.  What is the risks ratio to predict development of HAI given IL-6 -174G 
genotype? 
3.4.  What is the risks ratio to predict development of HAI given IL-10 -1082G 
genotype? 
3.5.  What is the risk ratio to predict development of HAI for each 10 point 
increase in pro-inflammatory cytokine?  
3.6.  What is the risk ratio to predict development of HAI for each 10 point 
increase in anti-inflammatory cytokine? 
3.7.  What is the risk ratio to predict development of HAI for each 10 point 
increase in ratio of pro- to anti-inflammatory cytokine? 
3.8.  Which variables are the strongest predictors of HAI development? 
3.9.  What is the final regression model for HAI? 
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CHAPTER 4.  RESULTS 
 
 
Study results are presented in this chapter. We begin with a description of study 
recruitment and baseline demographics including details surrounding the initial sepsis or 
suspected sepsis event. Next, we provide a detailed description among subjects 
developing HAI in this study. We then discuss several ICU outcome variables based on 
development of HAI and based on exaggerated or not exaggerated pro- or anti-
inflammatory response. Lastly, results are described by each specific aim.  
 
 
Recruitment 
 
Screening occurred over an 18 month period from February 2009 until July 2010. 
Recruitment details are shown in Figures 4-1 and 4-2. A total of 539 subjects were 
screened with 215 (39.9%) meeting inclusion criteria.  Among all patients meeting 
inclusion criteria, 105 (48.8%) met study related exclusion criteria, 32 (14.9%) had other 
reasons for exclusion, and 78 (36.3%) were enrolled. Approximately seven patients were 
screened for each patient enrolled. Some of the other reasons for exclusion included 
improvement and early transfer out of ICU, death, prior study subjects, or out of the 
window when evaluated. 
 
 
Demographics and Baseline Infections 
 
Subject demographics and clinical characteristics are shown in Table 4-1. The 
study population consisted of older (65.5 ± 12.6) male (97.9%) veterans who were 
admitted to the ICU primarily from the emergency room (48.7%) or general medical 
ward (30.8%) with sepsis as a primary or underlying condition. This population included 
a high percentage with co-morbidities (93.6%) with less than half (43.6%) having 
diabetes. This population had a high severity of illness given their high APACHE II (20.6 
± 6.4) and organ failure scores. Fifty (64.1%) subjects had at least two organ failures at 
baseline.  
 
Characteristics of baseline infection findings at ICU admission are shown in 
Table 4-2 and a rank percentage of baseline organisms identified is shown in Table 4-3.  
Among all baseline cultures, Staphylococcus Coagulase Negative was the most common 
microorganism, followed by Pseudomonas aeruginosa and Escherica coli. The most 
common type of infections among the 99 baseline infections were pneumonia (35.4% 
CAP or HACP) and urinary tract infection (31.3%).  All patients had been placed on 
empiric antibiotics for their definitive or suspected infections at baseline. No micro-
organisms were identified in 22 (28.2%) subjects. There were similar numbers of subjects 
with gram positive and gram negative infections.  Blood-stream infection accompanied 
32.0% of identified infections, with no source identified in 2 (3.4%) subjects with a blood 
stream infection.  Hypothermia or hyperthermia was present in 58 subjects. Baseline  
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Figure 4-1.  Subject Recruitment. 
 
539 Screened 
215 Met Inclusion 
78 Enrolled 
318 Did Not 
Meet Inclusion 
105 Study Specific Exclusion: 
• 36 Immunosuppressants 
• 28 Immunosuppressed 
• 5   Child-Pugh Class C 
• 35  No consent 
 
32 Other Exclusions 
• 1 Expired 
• 2 Improved 
• 8 Out of Window 
• 3 Prior subjects 
• 8 Transferred before Enrolled 
• 10 Unclear 
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Figure 4-2.  Monthly Subject Recruitment.  
 
Legend:  Down facing arrows denote protocols changes.  The first arrow represents a 
protocol clarification of SIRS criteria by adding > 10% bands.  The second arrow 
represents a protocol change to allow recruitment of MICU patients located in the SICU 
unit.  
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Table 4-1.  Demographic and Clinical Characteristics. 
 
 Variables 
All Subjects  
(n=78) 
Age (years) 65.5 ± 12.6 
Sex 
 Male 74 (94.9) 
Female 4 (5.1) 
Race 
 Black   30 (38.5) 
White 48 (61.5) 
BMI* 24.6 (10.1) 
Admitted From   
Emergency Room 38 (48.7) 
Another ICU 3 (3.8) 
Operating Room 4 (5.1) 
Spinal Cord Unit 9 (11.5) 
Ward 24 (30.8) 
Hospital Days Prior to ICU Admission† 1 (3) 
Prior Hospitalization for More than 1 Week 13 (16.7) 
Primary Reason for ICU Admission   
Sepsis or Severe Sepsis  33 (42.3) 
Septic Shock  20 (25.6) 
Respiratory Distress or Failure 13 (16.7) 
Other ‡  12 (15.4) 
Charlson Comorbidity Index > 0 § 73 (93.6) 
Diabetes 34 (43.6) 
Current Smoker 21 (26.9) 
Steroids Less than 1 mg/kg ‖ 17 (21.8) 
APACHE II 20.6 ± 6.4 
Sequential Organ Failure Score 6.9 ± 3.9 
Multiple Organ Dysfunction Score 1.9 ± 1.2 
Two or More Organ Failures  50 (64.1) 
 
Note: Data are reported as mean ± standard deviation, median (interquartile range), or 
count (percentage).  
* BMI denotes body mass index. BMI range 11.0 - 72.6. 
† Hospital days prior to ICU admission are reported as median (IQR), range 0 - 260. 
There were 22 (28.2%) patients who were in the hospital greater than 3 days and 4 (5.1%) 
who were hospitalized for more than 28 days. 
‡ Other reasons for ICU admission include: 3 post code, 2 non ST elevation myocardial 
infarctions, 2 gastro-intestinal bleeding, 1 congestive heart failure, 1 diabetic 
ketoacidosis, 3 post-op (carotid endarterectomy, knee replacement, gastric-tube 
placement with peritonitis). 
§ The Charlson Comorbitidy Index includes 19 medical conditions with weighted scores 
ranging from 1 to 6 for each condition and a total possible score of 0 - 37.116  
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Table 4-1. Continued.  
 
‖  Two subjects transferred from the ward had no prior steroids given on the ward or 
recorded in BCMA, but it was discovered upon later chart review that they received 1 
dose of steroids > 1 mg/kg in the ER. These subjects have been retained in all analysis 
following an intention to treat principle.   
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Table 4-2.  Baseline Infection Findings at ICU Admission. 
  
Variables 
All Subjects 
(n = 78) 
Definitive Infections 51 (65.4) 
Type of Infection* 
 Primary Bacteremia 2 
Aspiration Pneumonia  1 
Community Acquired Pneumonia 15 
Health Care Associated Pneumonia 20 
        Gastrointestinal or Intra-abdominal Infection 10 
Urinary Tract Infection 31 
Skin and Soft Tissue Infection 12 
Bone and Joint Infection 2 
CNS Infection 2 
Cardiovascular System Infection 3 
Malaria 1 
Number of Patients with 2 Sites of Infection 21 (26.9) 
Accompanying Bacteremia 25 (32.0) 
Type of Organism 
 Gram Positive 19 (24.3) 
Gram Negative 18 (23.1) 
Mixed Gram Positive and Gram Negative 8 (10.2) 
Fungal 4 (5.1) 
Mixed Fungal and Gram Positive  3 (3.4) 
Mixed Fungal and Gram Negative 3 (3.4) 
Mixed Fungal, Gram Positive, and Gram Negative 1 (1.3) 
No Organism Identified 22 (28.2) 
Hyperthermia (Temperature > 100.4) 23 (29.5) 
Hypothermia (Temperature < 96.8) 35 (44.9) 
SIRS 3.1 ± 0.7 
Temperature (°F) † 98.5 ± 3.0 
Respiratory Rate 30.9 ± 8.6 
White Blood Cell Count (Thousands) 18.7 ± 15.5 
Bands ‡ 22.2 ± 16.3 
Heart Rate Minimum 92.0 ±19.4 
Minimum SBP 85.6 (23.3) 
Number of Fluid Boluses Required § 3.3 ± 3.3 
Use of Vasopressors Required 25 (32.0) 
PaO2:FiO2 Ratio 210 ± 140 
C-reactive Protein 206.7 ± 156.7 
Lactate 3.2 ± 2.7 
Hours to ICU admission  4.6 (6.0) 
Timing to First Antibiotics 1.5 (3.75) 
Surgical Treatment 11 (14.1) 
Other Treatment 10 (12.8) 
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Table 4-2. Continued. 
 
 
Variables 
All Subjects 
(n = 78) 
Conventional Mechanical Ventilation 26 (33.3) 
Noninvasive Positive Pressure Ventilation 8 (10.3) 
 
Note: Data are reported as mean ± standard deviation, median (interquartile range), or 
count (percentage). The number of subjects is less than 78 for the following variables: C-
reactive protein (n = 65), lactate (n = 64), timing to ICU admission (n = 72), timing to 
first antibiotics (n = 71). 
* Type of infection includes all infections. There were a total of 99 suspected or 
definitive infections in 78 patients. The total number of infections in each category is 
shown. Gastrointestinal or intrabdominal infections include four with C-difficile colitis, 
five with peritonitis, and one with cholecystitis. Cardiovascular system infections include 
two with catheter related infection and one with endocarditis.  Bone and joint infections 
include one with osteomylitis and one with septic arthritis. CNS infection includes one 
with encephalitis and one with meningitis. Urinary tract infection includes one case of 
toxic shock syndrome post urology procedure detecting an abscess. 
† Temperature range from 93.5 to 104.3°F. 
‡ Manual differential counts were only done in 51 subjects. 
§ Fluid bolus range from 0 - 14 liters. 
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Table 4-3.  Most Common Baseline Micro-organisms. 
 
Organism All Organisms Cultured 
Staphylococcus coagulase negative (G+cocci) 26 (10.9) 
Pseudomonas aerugnosa (G-rods) 20 (8.4) 
E. Coli (G-rods) 20 (8.4) 
Klebsiella pneumoniae (G-rods) 18 (7.6) 
Candida albicans (yeast) 18 (7.6) 
Staphylococcus aureus (G+cocci) 16 (6.7) 
Enterococcus spp. (G+cocci) 16 (6.7) 
Probable Candida - no id (yeast) 16 (6.7) 
Serratia marcescens (G-rods) 6 (2.5) 
Clostridium spp. (G+rods) 5 (2.1) 
 
Note:  The number and percentage is shown.  This table is based on all cultures 
completed up to day 3.  Only organisms present in at least 5 cultures are shown.  There 
were 22 (28.2%) subjects with no baseline organism identified.   
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lactate and CPR levels were elevated.  Subjects received an average of 3.3 liters of fluid 
resuscitation on the day of ICU admission.  In general, fluids were given as a rapid bolus 
in response to hypotension but precise timing of fluid resuscitation was not recorded.  
The maximum volume received among participants was 14 liters in one patient, and there 
were 17 patients that did not require fluid resuscitation. Additionally, 25 (32.0%) 
required vasopressors and 34 (43.6%) required either conventional or non-invasive 
positive pressure ventilation at baseline. Median hours until first antibiotic and ICU 
admission were 1.5 and 4.6 hours, respectively. 
 
 
Description of First Health Care Associated Infection 
 
A total of 17 participants developed at least one HAI. Characteristics of the first 
HAI is shown in Table 4-4 and a rank percentages of organisms identified are shown in 
Table 4-5.  Candida was responsible for 11 (64%) of all identified first HAIs. There were 
three species of Candida identified (Candida albicans, Candida glabrata, Candida 
tropicalis) in addition to others not identified. The second most frequent organism was 
Staphylococcus Coagulase Negative. The primary type of infection was bloodstream 
infection (47.1%) followed by pneumonia (23.5%) and urinary tract infection (17.6%).  
 
Fever was present in approximately half (47%) who developed HAI and the 
average SIRS score was 2.1 ± 0.9.  Fluid bolus was required in 4 (23.5%) with the 
volume ranging from 0.5 to 5 liters. Three participants (17.7%) required vasopressors to 
support blood pressure, and 10 (58.8%) had moderate organ failure in 2 or more organs. 
Lactate and CPR levels were elevated.  
 
 Measureable environmental factors included invasive devices, staffing ratios, and 
receipt of blood products. All participants (100%) developing HAI had a central line, 
88.2% had a Foley catheter, and 70.5% were receiving mechanical ventilation (median 8 
days) at the time of first HAI. Three participants (17.7%) had at least one eight hour 
period with a nurse-to-patient ratio of more than 2:1 within 48 hours preceding the first 
HAI.  Seven participants (41.2%) received blood products within 48 hours preceding the 
first HAI.  
 
 
Differences in Variables among Those Who Did and Did Not Develop HAI  
 
 A summary of ICU outcomes is shown in Table 4-6 for all participants 
comparing those who did and did not develop HAI. There were several significant 
differences between those who did and did not develop HAI.  Those who developed HAI 
had a higher number of invasive devices (p = 0.04) at ICU discharge as well as a higher 
cummulative invasive device score (p < 0.0001). Those developeing HAI had a higher 
number of organs with at least moderate dysfuction (2.4 ± 2.3 vs. 1.1 ± 1.3, p = 0.04), 
required more use of vasopressors (64.7% vs. 27.9%, p=0.009) with more episodes of 
new shock (p = 0.003). Those developing HAI had an average ICU length of stay more   
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Table 4-4.  Description of First Health Care Associated Infection. 
 
Variables  
Developed HAI 
(n = 17) 
Day of ICU 9 (5) 
Type of Infection 
 Bloodstream Infection 8 (47.1) 
Pneumonia 4 (23.5) 
Urinary Tract Infection 3 (17.6) 
Gastrointestinal System Infection 1 (5.9) 
Cardiovascular System Infection-VASC 1 (5.9) 
Polymicrobial Infection 3 (17.7) 
Resistant Organism 4 (23.5) 
Fever or Hypothermia Present 8 (47.0) 
SIRS 2.1 ± 0.9 
Temperature  97.9 ± 1.8 
WBC 18.5 ± 9.5 
Respiratory Rate 30 ± 8 
Heart Rate Minimum 75 ± 15 
Minimum SBP 103.7 ± 18.7 
Number Requiring Fluid Bolus 4 (23.5) 
Use of Vasopressors Required 3 (17.7) 
PaO2:FiO2 ratio 196 ± 98 
Sequential Organ Failure Assessment 6.2 ± 4.7 
Multiple Organ Dysfunction Score 2.2 ± 1.6 
C-reactive Protein 146.2 ± 157.9 
Lactate 1.8 ± 1.5 
CPIS Score 3.5 ± 2.4 
Change in Antibiotics 12 (70.6) 
Receiving Mechanical Ventilation 12 (70.6) 
Duration of MV at Time of HAI* 8 (7) 
Cumulative Invasive Devise Score at Time of HAI 52.8 ± 26.7 
Invasive Devices Present: 
 Endotracheal Tube 10 (58.8) 
Tracheostomy 2  (11.7) 
Central Line 17 (100%) 
Foley Catheter 15 (88.2) 
Any Patient to Nurse Ratio > 2:1 in Preceding 48 Hours 3 (17.7) 
Received Blood Products in Preceding 48 Hours 7 (41.2) 
 
Note:  Data are reported as mean ± standard deviation, median (interquartile range), 
or count (percentage). 
* Two patients had prior mechanical ventilation during this ICU stay but were off 
for more than 48 hours at the time of their HAI.  One had received three days of MV 
and off five days when HAI developed; the other had been on MV five days, and off 
six days when HAI developed. 
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Table 4-5.  First HAI Micro-organisms (Ranked). 
 
Organisms Rank and Percentage 
Candida albicans* 5 (25) 
Staphylococcus coagulate negative † 4 (20) 
Candida glabrata ‡ 2 (10) 
Candida tropicalis ‡ 2 (10) 
Candida spp not identified § 2 (10) 
Acinetobacter baumanni ‖ 1 (5) 
Clostridium difficile 1 (5) 
Escherica coli ¶ 1 (5) 
Klebsiella pneumoniae ¶ 1 (5) 
Pseudomonas aeruginosa # 1 (5) 
 
Candida species involved 11 (64%) of all 17 identified first HAIs. 
* 2 HCAP, 3 fungemia. One Candida albicans was mixed with Klebsiella 
pneumoniae in the BAL. 
† 2 blood stream infections, 1 HCAP, 1 Cardiovascular system infection –VASC. 
Two Coagulate Negative Staphylococcus were mixed, one with Candida albicans in 
the BAL and the other with Candida tropicalis in the blood 
‡ 2 fungemia 
§ 2 UTI, 1 with fungemia 
‖ UTI 
¶  HCAP 
# VAP 
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Table 4-6.  Differences in Variables among Those Who Did and Did Not Develop Health Care Associated Infections. 
 
Variables 
All subjects 
(n = 78) 
No HAI 
(n = 61) 
Developed HAI 
(n = 17) 
P  
Value 
Any HAI Develop During ICU Stay 17 (21.8) 0 (0.0) 17 (100) .  
Number of Invasive Devices at Discharge 3.3 ± 1.3 3.1 ± 1.3 3.8 ± 1.3 0.04 
Total Invasive Device Score at Discharge 35.6 ± 35.7 23.9 ± 23.0 77.7 ± 41.8 < 0.0001 
SOFA Score at Discharge 4.6 ± 4.7 4.1 ± 4.2 6.6 ± 5.8 0.10 
MODS Score at Discharge 1.4 ± 1.6 1.1 ± 1.3 2.4 ± 2.3 0.04 
SIRS Score 1.8 ± 0.9 1.9 ± 1.0 1.7 ± 0.8 0.35 
Mechanical Ventilation Duration (n = 34) 8.0 ± 6.5 5.9 ± 4.7 11.1 ± 7.6 0.03 
Use of Vasopressors during ICU Stay 28 (35.9) 17 (27.9) 11 (64.7) 0.009 
Duration of Vasopressor Use (Days) 3.9 ± 3.0 3.9 ± 3.1 4.1 ± 3.2 0.87 
Any New Shock during ICU Stay 9 (11.5) 3 (4.9) 6 (35.3) 0.003 
Blood Products during ICU Stay 44 (56.4) 31 (50.8) 13 (76.5) 0.10 
ICU Survival 64 (82.1) 52 (85.3) 12 (70.6) 0.17 
Discharge Destination . . . 0.14 
Remained in ICU 1 (1.3) 0 (0.0) 1 (5.9) . 
Ward 56 (71.8) 46 (75.4) 10 (58.8) . 
Spinal Cord Unit 7 (9.0) 6 (9.8) 1 (1.5) . 
Morgue 14 (18.0) 9 (14.8) 5 (29.4) . 
Duration of ICU stay 8.0 ± 6.2 6.4 ± 4.0 15.3 ± 7.1 < 0.0001 
Readmissions to ICU within 28 Days 12 (15.4) 8 (13.1) 4 (23.5) 0.06 
Any Nurse Patient Ratio Greater than 2:1 14 (18.0) 11 (18.0) 3 (17.7) 1.00 
Steroids Use during ICU Stay 40 (51.3) 26 (42.6) 14 (82.4) 0.005 
Insulin Use during ICU Stay 57 (73.1) 42 (68.9) 15 (88.2) 0.13 
Received Blood Products during ICU Stay 44 ( 56.4) 31 (50.8) 13 (76.50 0.09 
 
Note:  Data are reported as mean ± standard deviation, median (interquartile range), or count (percentage). 
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than twice compared to those not developing HAI, and required a longer duration of 
mechanical ventilation. There was a higher rate of steroid use in those developing HAI 
compared to those who did not (82.4% vs. 42.6%, p = 0.005). Patients developing HAI 
also had a trend (p = 0.06) towards higher ICU readmissions rate within 28 days as 
compared to those who did not develop HAI. 
 
 
Differences in Variables by Pro- and Anti-inflammatory Cytokine Quartiles among 
Those Who Did and Did Not Develop HAI 
 
A summary is provided in Table 4-7 comparing participants with high baseline 
systemic inflammation (fourth quartile) to participants without high baseline systemic 
inflammation (first-third quartiles) for both the pro-inflammatory cytokine IL-6 and the 
anti-inflammatory cytokine IL-10.  Steroid use was the only significant difference among 
participants with a high anti-inflammatory response versus those without (84.2% vs. 
40.7%, p = 0.0013). Among those with a high pro-inflammatory response there were 
several significant differences in comparison to those with a lower pro-inflammatory 
response. Organ dysfunction was higher, and there was a three fold higher number of 
participants requiring vasopressors (73.7% vs. 23.7%, p < 0.0001).There was also a 
higher percentage of steroid use (73.7% vs. 44.1%,  p = 0.03), as well as participants with 
arrythmias (52.6% vs. 18.6%, p = 0.007).  ICU Survival was similar for all participants 
regardless of baseline pro- or anti-inflammatory cytokine level.  
 
 
Cytokine and Genotype Measurements 
 
 Cytokines were measured by Luminex in batches. Details are described in the 
methods section. The detection limits for each cytokine was 3.2 pg/ml and 10,000 pg/ml. 
A total of 5 (6.4%) of IL-6 levels and 29 (37.2%) of IL-10 levels were below the 
detection limit. In these cases, a surrogate of 3.2 pg/ml was used for statistical purposes. 
 
 DNA isolation occurred in batches during recruitment and after recruitment was 
complete. Genotyping was perfomed after study recruitment was complete using End 
Point Genotyping by Real-Time PCR.  The LightCycler® 480 software (version LCS480 
1.5.0.39)  by Roche (Mannheim, Germany) provided automated genotyping calls for each 
participant. A call of either Allele X, Allele Y, Both Alleles, Unknown, or Negative was 
provided for each of the 96 wells. Gentotypes for Allele X, Allele Y, and Both Alleles 
were described in Table 3.2.  A negative call was received for the negative controls,  
empty wells, and for other possible reasons such as sample quality, inhibition, or 
primer/dimer formation. Unknown calls were received when the software was unable to 
determine the genotype.  
 
A test run was performed to optimize the PRC reaction which included the first 10 
participant’s samples under conditions described in the methods section. Replication was 
not observed until 30 cycles during the test run; therefore, the cycle time was increased to 
50 from 45 cycles based on expert guidance from a MRC scientists who assisted with 
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Table 4-7.  Differences in Variables  Pro- and Anti-inflammatory Cytokine Quartiles. 
 
 
Pro-inflammatory Cytokine: IL-6  Anti-inflammatory Cytokine: IL-10 
Variables 
1st-3rd 
Quartiles 
4th  
Quartile 
P 
Value 
 1st-3rd 
Quartiles 
4th 
Quartile 
P 
Value 
Number of Subjects 59 19 
 
 59 19 
 Any HAI Develop During ICU Stay 11(18.6) 6 (31.6) 0.55  12 (20.3) 5 (26.3) 0.43 
Invasive Device Score at Discharge 31.9 ± 33.5 47.0 ± 40.1 0.15  32.4 ± 34.3 45.6 ± 39.1 0.19 
Invasive Devices at Discharge 3.2 ± 1.2 3.5 ± 1.7 0.45  3.3 ± 1.3 3.4 ± 1.6 0.77 
SOFA Score at Discharge 3.7 ± 3.6 7.5 ± 6.4 0.02  4.2 ± 4.3 6.1 ± 5.6 0.19 
MODS Score at Discharge 1.1 ± 1.3 2.2 ± 2.1 0.04  1.2 ± 1.6 1.8 ± 1.8 0.23 
SIRS Score 1.8 ± 0.9 2.0 ± 0.9 0.50  1.9 ± 1.0 1.7 ± 0.9 0.66 
Mechanical Ventilation Duration* 7.1 ± 5.6 10.1 ± 8.3 0.32  7.1 ± 5.6 10.2 ± 8.9 0.29 
Use of Vasopressors during ICU stay 14 (23.7) 14 (73.7) <0.0001  18 (30.5) 10 (52.6) 0.08 
Any New Shock during ICU stay 6 (10.2) 3 (15.8) 0.68  7 (11.9) 2 (10.5) 1.00 
Blood Products during ICU stay 32 (54.2) 14 (73.7) 0.60  33 (55.9) 11 (57.9) 0.88 
ICU Survival 50 (84.8) 14 (73.7) 0.31  49 (83.1) 15 (79.0) 0.74 
Discharge Destination . . 0.22  . . 0.37 
Remained in ICU 0 (0.0) 1 (5.3) .  0 (0.0) 1 (5.3) . 
Ward 44 (74.6) 12 (32.2) .  44 (74.6) 12 (63.2) . 
Spinal Cord Unit 6 (10.2) 1 (5.3) .  5 (8.5) 2 (10.6) . 
Morgue 9 (15.3) 5 (26.3) .  10 (17.0) 4 (21.1) . 
Duration of ICU stay 7.4 ± 5.6 10.1 ± 7.4 0.16  7.5 ± 5.7 9.7 ± 7.2 0.24 
Readmissions to ICU within 28 days 9 (15.3) 3 (15.9) 0.26  8 (13.6) 4 (21.1) 0.40 
Any Nurse Patient Ratio >  2:1 13 (22.0) 1 (5.3) 0.16  13 (22.0) 1 (5.3) 0.16 
Steroids Use during ICU stay 26 (44.1) 14 (73.7) 0.03  24 (40.7) 16 (84.2) 0.0013 
Insulin Use during ICU stay 43 (72.9) 14 (73.7) 0.95  46 (78.0) 11 (57.9) 0.09 
Arrhythmias 11 (18.6) 10 (52.6) 0.007  14 (23.7) 7 (36.8) 0.26 
Cardiac Arrest 13 (22.0) 7 (36.8) 0.23  15 (25.4) 5 (26.3) 0.94 
 
* Duration of mechanical ventilation includes data for 34 subjects who received mechanical ventilation, n=24 versus 10, 
respectively. 
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LightCycler initial set-up and with calculations required for initial reaction volumes.  The 
genotype results for IL-6 under these conditions included 32 Negatives and 5 Unknowns. 
Applied Biosystems technical support advised that although replication did not begin 
until 30 cycles, it is more appropriate for end point genotyping not to increase cycle time 
beyond 45 cycles.  All samples were re-tested for IL-6 genotyping using the original test 
conditions (45 cycles) and resulted in only 2 undetermined genotypes (1 negative and 1 
unknown call). These 2 missing genotypes were available from the initial test run.    
 
Genotyping for IL-10 was performed as described in the methods section. The 
initial undetermined calls were 30 unknown and 1 negative. The reaction was optimized 
by increasing the temperature to 62°C, reducing the number of unknowns to 7. Manual 
calls were required for these 7 subjects: 2, 22, 27, 31, 50, 58, and 69. These subjects were 
manually called heterozygotes based upon visual clustering and endpoint fluorescence 
values.  All unknown calls had a confidence score less than 0.50 and endpoint 
fluorescence values were not significantly higher than each other. Although the software 
algorithm is proprietary, genotypes that were automatically called included an endpoint 
fluorescence of at least one or more fold higher than the lower endpoint fluorescence 
value. The endpoint fluorescence value for those called as heterozygous contained 
differences but they were generally much less than a fold difference.    
 
 
Genotype Allele Frequencies 
 
 The allele frequencies are shown for rs1800795 and rs1800896 genotypes in 
Table 4-8 and 4-9, respectively.  These tables also show allele frequencies for all subjects 
as well as white and black sepsis patients who do and do not develop HAI. Note that 
there were no significant differences between the percentage of blacks and white sepsis 
patients who do and do not develop HAI (23.3% vs. 20.8%, p = 0.79).  
 
For rs1800795, there were no significant allele frequency differences among those 
who do and do not develop HAI (p = 0.59); however, when examining racial differences 
in genotype and controlling for those who do and do not develop HAI differences were 
noted. There was a significant difference in rs1800795 genotype among black patients 
with sepsis who did not develop HIA compared to whites patients with sepsis who did 
not develop HAI (p = 0.0056). Specifically, black patients had a lower CG (17.4% vs. 
42.1%) and higher GG (82.6% vs. 42.1%) than white patients. There were no racial 
differences when comparing white and black sepsis patients who developed HAI (p         
= 1.0). 
 
For rs1800896, there were no significant allele frequency differences among those 
who do and do not develop HAI (p = 0.16). There were no significant racial differences 
among those who did (p = 1.0) and did not develop HAI (p = 0.41). 
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Table 4-8.  RS1800795 Genotype and Allele Frequencies. 
 
Population Number CC CG GG 
All 78 0.090 0.359 0.551  
White  48  0.146  0.437 0.417  
     HAI 10 0.100 0.500 0.400 
     No HAI 38 0.158 0.421 0.421 
Black 30  0.000  0.233 0.767  
     HAI 7 0.000 0.429 0.571 
     No HAI 23 0.000 0.017 0.826 
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Table 4-9.  RS1900896 Genotype and Allele Frequencies. 
 
Population Number AA AG GG 
All 78 0.218 0.488 0.295 
White 48  0.271 0.437 0.292  
    HAI 10 0.100 0.500 0.400 
    No HAI 38 0.316 0.421 0.263 
Black 30  0.133 0.567 0.300  
    HAI 7 0.000 0.571 0.429 
    No HAI 23 0.174 0.565 0.261 
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Genotype Comparisons to HapMap 3 Reference Population 
 
 There were differences in the genotype of sepsis patients as compared to a normal 
HapMap3 reference population (see Table 4-10).  White (and not black) patients with 
sepsis had a significantly different (p = 0.02) IL-6 genotype with higher GG (41.7% 
versus 24.8%) and lower CC (14.6% versus 31.9%) genotypes when compared to a 
normal reference. When examining IL-10 genotypes, black (and not white) patients with 
sepsis had a significantly higher GG (30.0% versus 12.2%) and lower AA (13.3% versus 
44.9%) genotype when compared to a normal reference.   
 
 
Baseline Cytokine Levels by Genotype and Haplotypes 
 
Plasma cytokine levels were right skewed and required log transformation for 
statistcs requiring a normal disturbution. Table 4-11 provides a summary of plasma IL-6 
and IL-10 levels. Median IL-6 levels were higher than median IL-10 levels. Table 4-12 
provides cytokine levels and their ratio for each genotype. Median IL-6 levels were 
highest among participants with the CC IL-6 genotype and also among participants with 
the GG IL-10 genotype. Median IL-10 levels were highest among participants with the 
AA IL-10 genotype and also among participants with the CG IL-6 genotype. Figures 4-3, 
4-4, 4-5 and 4-6 provide box-plots of pro- and anti-inflammatory cytokines and their 
ratios by for IL-6 and IL-10 genotypes.  Each figure contains two images. The top image 
shows the skewed data distribution prior to log transformation, and the lower image 
shows the log transformed data distribution. 
 
 
Aim 1 
 
The primary goal of aim one was to investigate whether baseline protein 
expression levels of pro-inflammatory cytokines, anti-inflammatory cytokines, or their 
ratios influence the development of subsequent HAI in patients with sepsis.  
 
There was no significant difference in levels of pro-inflammatory cytokine, anti-
inflammatory cytokine, or their ratio among subjects who did and did not develop at least 
one HAI during their ICU stay. This aim was explored by comparing lower quartiles to 
the higher fourth quartile for proinflammatory cytokine IL-6 and anti-inflammatory 
cytokine IL-10, as well as comparing their ratios. Patients in the fourth quartile were 
considered to have an exaggerated inflammatory response as compared to those in other 
quartiles.  Specifically, an exaggerated pro-inflammatory response was present in 6 
(31.6%) compared to 11 (18.6%) participants without an exaggerated pro-inflammatory 
response who developed subsequent HAI. This difference was not significant (p = 0.55).   
Likewise, an exaggerated anti-inflammatory response was present in 5 (26.3%) compared 
to 12 (20.3) participants without an exaggerated anti-inflammatory response who 
developed subsequent HAI. This difference was also not significant (p = 0.43).  There 
was also no significant difference in the log of proinflammatory to anti-inflammatory 
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Table 4-10.  Genotype Comparisons of IL-6 and IL-10 SNPs among Sepsis and HapMap Reference Population.   
 
 
 
Genotype 
 
HapMap  
(n = 324) 
 
Sepsis 
(n = 78) 
 
P 
Value 
HapMap: 
Black 
(n = 98) 
Sepsis 
Black 
(n = 30) 
 
P 
Value 
HapMap 
White 
(n = 226) 
Sepsis 
White 
(n = 48) 
 
P 
Value 
IL-6 . . 0.01 . . 0.60 . . 0.02 
CC 72 (22.2) 7 (9.0) . 0 (0) 0 (0) . 72 (31.9) 7 (14.6) . 
CG 116 (35.8) 28 (35.9) . 18 (18.4) 7 (23.3) . 98 (43.4) 21 (43.8) . 
GG 136 (42.0) 43 (55.1) . 80 (81.6) 23 (76.7) . 56 (24.8) 20 (41.7) . 
          
IL-10 . . 0.35 . . 0.002 . . 0.54 
AA 92 (28.4) 17 (21.8) . 44 (44.9) 4 (13.3) . 48 (21.2) 13 (27.1) . 
AG 158 (48.8) 38 (48.7) . 42 (42.9) 17 (56.7) . 116 (51.3) 21 (43.8) . 
GG 74 (22.8) 23 (29.5) . 12 (12.2) 9 (30.0) . 62 (27.4) 14 (29.2) . 
 
Note: The reference population is the HapMap 3.  The HapMap 3 sample included in this comparison includes normal 
individuals from African ancestry in Southwest USA (black) and Utah residents with Northern and Western European 
ancestry (white).109
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Table 4-11.  Range of Plasma IL6 and IL10 Levels. 
 
  Median (n=78) 
Inter-quartile 
Range Minimum Maximum 
IL-6 pg/ml 167.9 48.4 - 345.5 3.2 3862.4 
IL-10 pg/ml 20.8 3.2 - 134.4 3.2 2066.5 
Log IL-6 pg/ml 5.1 3.9 - 5.8 1.2 8.3 
Log IL-10 pg/ml 3.0 1.2 - 4.9 1.2 7.6 
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Table 4-12.  Median  and Inter-quartile Range of Pro- and Anti-Inflammatory Cytokine 
Levels by Genotypes. 
 
Variables 
IL-6 Levels pg/ml 
(n = 78) 
IL-10 Levels pg/ml 
(n = 78) 
IL6:IL10 Ratio 
(n = 78) 
Genotype: IL-6 SNP 
 CC 260.2 (90.4 - 406.8) 8.8 (3.2 - 36.3) 10.2 (6.1 - 81.3) 
CG 176.7 (67.4 - 404.5) 68.7 (4.1 - 369.8) 3.1 (1.3 - 12.3) 
GG 119.0 (28.0 - 293.1) 16.4 (3.2 - 132.8) 4.9 (1.5 - 17.9) 
C Allele 195.3 (67.9 - 406.8) 36.2 (3.2 - 150.7) 5.7 (1.4 – 19.8) 
    Genotype: IL-10 SNP 
 AA 86.3 (24.5 - 257.8) 58.3 (18.9 - 139.7) 2.2 (1.5 - 4.9) 
GA 163.4 (43.5 - 293.1) 3.2 (3.2 - 60.7) 9.2 ( 1.4 - 27.1) 
GG 242.3 (98.1 - 633.7) 43.5 (11.2 - 243.1) 6.1 (1.8 - 15.8) 
A Allele 157.1 (29.9 - 284.6) 10.5 (3.2 - 106.7) 4.7 (1.4 – 20.9) 
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Figure 4-3.  Box Plot of Plasma IL-6 levels by IL-6 Genotypes Pre and Post Log 
Transformation. 
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Figure 4-4.  Box Plot of Plasma IL-10 levels by IL-10 Genotypes Pre and Post Log 
Transformation. 
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Figure 4-5.  Box Plot of Plasma IL-6:IL10 ratios by IL-16 Genotypes Pre and Post Log 
Transformation. 
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Figure 4-6.  Box Plot of Plasma IL-6:IL10 ratios by IL-10 Genotypes Pre and Post Log 
Transformation. 
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ratios among those who did and did not develop subsequent HAI (1.8 ± 1.5 vs. 1.6 ± 1.8, 
p = 0.55).  Cytokine levels were right skewed; thus, non-parametric tests were performed 
to provide a comparison of median values among participants who did and did not 
develop HAI. Median cytokine measurements are shown in Table 4-13. There were no 
significant differences in baseline pro-inflammatory cytokines, anti-inflammatory 
cytokines, or their ratios among participants who did and did not develop at least one 
HAI during their ICU stay.   
  
 
Aim 2 
 
The goal of aim two was to investigate the variance in cytokine genes to 
determine if they influence levels of protein expression or development of HAI.   
  
The variance in cytokine genes were determined by SNP analysis. The 
distribution of subjects per genotype is shown in Table 4-14. An ANOVA was performed 
to examine the difference in cytokine means for each genotype.  Table 4-15 and Figure 
4-7 summarize the cytokine levels for each SNP. There were no significant differences in  
plasma IL-6 levels based on SNP rs1800795.  Both homozygous AA and GG genotypes 
for IL-10 SNP rs1800896 were significantly higher (0.02) that the heterozygous GA.  
 
Table 4-14 summarizes development of HAI by genotype and haplotype. There 
were no statistically significant differences among genotypes or haplotypes for 
development of HAI. There were no CC_AA, CC_GA, or GG_AA haplotypes among the 
17 participants who developed HAI.  The most common haplotype, was the heterozygous 
CG_GA.  This haplotype is also where the highest percentage of HAIs occurred but this 
was not significant. 
 
 
Aim 3   
 
The goal of aim three was to investigate the effects of protein expression levels, 
genetic variation, and environment on development of HAI.  A series of Cox regression 
analyses were performed among those who did and did not develop HAIs during ICU 
stay (or up to 28 days in those with a prolonged ICU stay) controlling for a number of 
potentially confounding variables. Table 4-16 provides a summary of variables testing 
for inclusion into the multivariate model. Only variables with a p-value of less than 0.25 
were included in the multivariate regression model (Table 4-17). There were only four 
females in the study and it was not appropriate to include gender in the model (HR = 
1313884). 
 
Aim three included a series of questions pertaining to risk of developing HAIs.  In 
general, a hazard ratio greater than 1 indicates a higher risk of developing an event, in 
this case health care associated infections, and a hazard ratio less than 1 indicates a lower  
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Table 4-13.  Comparison of Cytokine Levels among Subjects Developing HAI. 
 
Variables 
No HAI 
(n = 61) 
Developed HAI 
(n = 17) 
P  
Value 
IL-6 pg/ml 157.1 (251.8) 229.7 (571.4) 0.21 
IL-10 pg/ml 18.9 (129.6) 34.8 (144.6) 0.55 
IL-6:IL-10 ratio 4.7 (16.4) 6.2 (11.6) 0.78 
 
Note: Median and interquartile range shown. 
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Table 4-14.  SNP Genotypes and Haplotypes for All Subjects by HAI Development and Pro- and Anti-inflammatory Cytokine 
Quartiles. 
 
        
 
Pro-inflammatory Cytokine: IL-6  Anti-inflammatory Cytokine: IL-10 
Variables 
All 
Subjects No HAI HAI P Value 
1st-3rd 
Quartiles 
4th  
Quartile 
P  
Value 
 1st-3rd 
Quartiles 
4th 
Quartile 
P  
Value 
N 78 61 17 
 
59 19 
 
 59 19 
 IL-6 . . . 0.59 . . 0.67  . . 0.56 
CC 7 (9.0) 6 (9.8) 1 (5.9) . 5 (8.5) 2 (10.5) .  6 (10.1) 1 (5.3) . 
CG 28 (35.9) 20 (32.8) 8 (47.1) . 20 (33.9) 8 (42.1) .  19 (32.2) 9 (47.3) . 
GG 43 (55.1) 35 (57.4) 8 (47.1) . 34 (57.6) 9 (47.4) .  34 (57.6) 9 (47.4) . 
        
 
   IL-10 . . . 0.15 . . 0.26  . . 0.57 
AA 17 (21.8) 16 (26.2) 1 (5.9) . 15 (25.4) 2 (10.5) .  12 (20.3) 5 (26.3) . 
GA 38 (48.8) 29 (47.5) 9 (52.9) . 29 (49.2) 9 (47.4) .  32 (54.3) 6 (31.6) . 
GG 23 (29.5) 16 (26.2) 7 (41.8) . 15 (25.4) 8 (42.1) .  15 (25.4) 8 (42.1) . 
Haplotype 
 (IL-6_IL10) . . . 0.55 . . 0.47 
 
. . 0.21 
CC_AA 1 (1.3) 1 (1.6) 0 (0) . 1 (1.7) 0 (0) .  0 (0) 1 (5.3) . 
CC_GA 4 (5.3) 4 (6.6) 0 (0) . 2 (3.4) 2 (10.5) .  4 (6.8) 0 (0) . 
CC_GG 2 (2.3) 1 (1.6) 1 (5.6) . 2 (3.4) 0 (0) .  2 (3.4) 0 (0) . 
CG_AA 3 (3.9) 3 (4.9) 0 (0) . 2 (3.4) 1 (5.3) .  2 (3.4) 1 (5.3) . 
CG_GA 18 (23.1) 13 (21.3) 5 (29.4) . 14 (23.7) 4 (21.1) .  13 (22.0) 5 (26.3) . 
CG_GG 7 (9.0) 4 (6.6) 3 (17.7) . 4 (6.8) 3 (15.8) .  4 (6.8) 3 (15.8) . 
GG_AA 13 (16.7) 12 (19.7) 1 (5.9) . 12 (20.3) 1 (5.3) .  10 (17.0) 3 (15.8) . 
GG_GA 16 (20.5) 12 (19.7) 4 (25.5) . 13 (22.0) 3 (15.8) .  15 (25.4) 1 (5.3) . 
GG_GG 14 (18.0) 11 (18.0) 3 (17.7) . 9 (15.3) 5 (26.3) .  9 (15.3) 5 (26.3) . 
IL6 C Allele 35 (44.9) 26 (42.6) 9 (52.9) 0.45 25 (42.4) 10 (52.6) 0.43 
 
25 (42.4) 10 (52.6) 0.43 
IL10 A Allele 55 (70.5) 45 (73.8) 10 (58.8) 0.23 44 (74.6) 11 (57.9) 0.17  44 (74.6) 11 (57.9) 0.17 
 
 
65 
 
  
Table 4-15.  Cytokine levels by Genotype. 
 
Genotype: 
IL-6 SNP 
Log 
 IL-6 
Standard 
Deviation 
Genotype:  
IL-10 SNP 
Log  
IL-10 
Standard 
Deviation 
CC 5.3 0.6 AA 3.9 0.5 
CG 5.1 0.3 GA 2.6 0.3 
GG 4.6 0.3 GG 3.8 0.4 
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Figure 4-7.  Log Plasma Cytokine Levels by Genotype. 
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Table 4-16.  Univariate Cox Regression Hazard Ratios for Development of HAI. 
 
Variables 
Parameter 
Estimate 
Standard 
Error Chi-Square 
P 
Value 
Hazard 
Ratio 
Age 0.070 0.027 6.481 0.011 1.072 
Race 1.150 0.786 2.137 0.154 3.157 
Body Mass Index (BMI) -0.024 0.035 0.480 0.488 0.976 
Obesity (BMI > 30) -0.199 0.599 0.110 0.740 0.820 
Diabetes -0.638 0.595 1.152 0.283 0.528 
APACHE II 0.067 0.054 1.497 0.221 1.069 
Baseline CRP 0.002 0.002 1.695 0.193 1.002 
Baseline Plasma IL-10 0.000 0.000 0.340 0.560 1.000 
Baseline Plasma IL-6 0.000 0.000 0.285 0.593 1.000 
IL-6:IL-10 Ratio -0.009 0.018 0.237 0.626 0.991 
IL-6 Genotype: CG  1.435 0.665 4.656 0.031 4.200 
IL-6 Genotype: CC  1.563 1.203 1.688 0.194 4.775 
IL-10 Genotype: GA  1.391 0.817 2.895 0.089 4.018 
IL-10 Genotype: AA  1.348 0.892 2.284 0.131 3.849 
Corticosteroids 0.283 0.900 0.099 0.753 1.327 
Received Insulin during ICU Stay -1.184 0.805 2.163 0.141 0.306 
Any Blood Products during ICU Stay -0.123 0.622 0.039 0.844 0.885 
Received Antibiotics Prior to ICU -0.823 0.696 1.396 0.237 0.439 
Appropriate Antibiotics in First 24 H 0.468 1.053 0.197 0.657 1.597 
Invasive Device Score at HAI -0.037 0.016 5.546 0.019 0.963 
Patient: Nurse Ratio > 2 to 1  0.494 0.616 0.644 0.422 1.639 
 
Note: IL-6 and IL-10 genotype comparisons are made to GG genotype.  
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Table 4-17.  Final Multivariate Cox Regression Model. 
 
Variables 
Chi-
Square P Value 
Hazard 
Ratio 
Confidence 
Interval 
APACHE II 5.115 0.0237 1.241 1.029 - 1.495 
Invasive Device Score at HAI 11.370 0.0007 0.908 0.086 - 0.961 
Received Antibiotics Prior to ICU 4.965 0.0259 0.106 0.015 - 0.763 
IL-6 Genotype CC 4.858 0.0275 28.097 1.447 - 545.653 
IL-6 Genotype CG 7.456 0.0063 14.959 2.146 – 104.295 
 
Note: IL-6 Genotypes are compared to GG genotype. 
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risk of developing an event. Each question was answered based on univariate cox 
regression modeling:  
• The hazard ratio to predict development of HAIs for APACHE II is 1.069. For 
each 10 point increase in APACHE II score the risk ratio or hazard ratio is e0.06656 
x 10 = 1.956. For a 10 point increased in APACHE II score, there is a 95.6 percent 
increase in the risk of developing a HAI. 
• The hazard ratio to predict development of HAI for each additional invasive 
devise is e-0.03742 = 0.963. For an additional invasive devise score there was a 
3.7% lower risk of developing a HAI. The cumulative invasive devise score at the 
time of HAI had been compared to the invasive devise score at ICU discharge 
among participants who did not develop a HAI. 
• The hazard ratio to predict development of HAIs given IL-6 -174G genotype CG 
compared to GG is e1.43513 = 4.200, and for IL6 genotype CC compared to GG the 
hazard ratio is e1.56334 = 4.775.  Presence of the GG genotype has a four-fold 
increase in risk for development of HAI. 
• The hazard ratio to predict development of HAIs given IL-10 -1082G 
genotypeIL-10 GA compared to GG is e1.39081 = 4.018,  AA compared to GG is 
e1.34786 = 3.849. Presence of the GG genotype has a four-fold increase in risk for 
development of HAI 
The hazard ratio to predict development of HAIs for each 10 point increase in 
pro-inflammatory cytokine based on plasma IL-6 is e0.0001308 x 10 = 1.001. For a 10 
point increase in IL-6 there is a 0.1% increase in developing a HAI. 
• The hazard ratio to predict development of HAIs for each 10 point increase in 
anti-inflammatory cytokine based on plasma IL-10 is e0.0002799x10 = 1.002. For a 10 
point increase in IL-10 there is a 0.3% increase in developing a HAI. 
• The hazard ratio to predict development of HAIs for each 10 point increase in 
ratio of pro- to anti-inflammatory cytokine is e-0.00890x10  =  0.915. For a 10 point 
increase in IL-6:IL10 ratio there is a 8.5% lower risk of developing a HAI. 
 
The multivariate model included several predictors associated with HAI 
development. All variable tested in univariate cox regression with a p <0.25 were 
included in the final model. These variables included: age, race, APACHE II score, 
invasive device score at first HAI, received insulin during ICU stay, baseline C-reactive 
protein, received antibiotics prior to ICU, IL-6 genotype, and IL-10 genotype. Only 
variables with of probability of < 0.05 were included in the final model. As some IL-6 
genotypes were not significant, a dichotomous variable for genotype was created to 
compared the CG and CC to the GG alleles. The final regression model is shown in 
Table 4-17. 
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CHAPTER 5.  DISCUSSION 
 
 
The purpose of this study was to determine the impact of baseline systemic 
inflammation, genetic variability, and environment on the development of HAI among 
patients with sepsis during their ICU stay.  The sample consisted of 78 subjects, with 17 
developing at least one HAI during or attributed to their ICU stay. Major findings in 
general and by aim will be described as well as strengths, limitations, and implications 
for these findings. 
 
 
Major Findings 
 
 
Baseline Infections 
 
 The most common infection responsible for sepsis at ICU admission in this study 
was pneumonia, followed by UTI, skin and soft tissue infection, and gastrointestinal or 
intrabdominal infection. The pattern of infection (site and organism) differs across ICU 
populations as described in the discussion. This study focuses on medical ICU patients. 
Our finding of pneumonia as the primary cause of sepsis causing ICU admission is in 
agreement with some studies43,92 but urinary tract infections may precede pneumonia as 
the primary cause.42    
 
We found a significantly higher percentage of patients with high IL-6 levels 
versus lower levels who developed arrhythmias during their ICU stay (52.6% vs. 18.6%, 
p = 0.007). The median IL-6 difference was 303.3 vs. 98.1 (p = 0.0008) for those who 
developed arrhythmias versus those who did not. This is consistent with emerging 
literature.  Aviles, et al. have shown that atrial fibrillation is associated with elevated 
CPR levels, 117  and Boos provides a summary of four studies that found associations of 
elevated CRP and IL-6 levels with atrial fibrillation and one study that did not.118 
 
This population was composed primarily of males (97.9%), thus limiting 
conclusion about females.  It is well documented that males have a higher rate of 
infections;119 however; this study included only 4 women. One female (25%) and 16 
males (21.6%) developed HAI. This sample does not include enough females for a valid 
comparison.  There were no differences in the rate of HAI developed between white and 
black patients in this study; however, we did find a difference in genotype among white 
and black patients with sepsis who did and did not develop HAI. The literature reports a 
higher incidence of infections in blacks as compared with whites.120 
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First Health Care Associate Infection 
 
The percentage of HAI caused by Candida (64%) was a surprising finding in this 
study.  Typically, the expected leading organisms associated with HAI are gram positive 
(such as Coagulate-negative Staphylococcus, Staphylococcus aureus, and Enterococcus 
spp.).43  This is a shift away from gram negative organisms in the past, and now  Candida 
species have emerged as the fourth most common cause of health care associated blood 
stream infections.121,122  There were three species of Candida identified (Candida 
albicans, Candida glabrata, Candida tropicalis) in addition to unidentified Candida 
species.  Colonization of the urinary tract with Candida is becoming more common and 
the line between colonization and urinary tract infection is not easily distinguished.123 
Among this sample, there were only two urinary tract infections (Candida species not 
identified). There were two Candida albicans pneumonias, and all of the remaining 
Candida infections were bloodstream infections (3 Candida albicans, 2 Candida 
glabrata, 2 Candida tropicalis). The incidence of fungemia in the ICU had been 
increasing and there have also been changes in the species pattern of Candida.  Candida 
albicans was the primary species in the 1980s, but now almost half of Candida infections 
are non-albicans.124 The mortality associated with Candida glabrata is higher than 
Candida albicans, 121,124 and Candida glabrata has been reported as the second most 
frequent cause of Candidemia in US hospitals.121  Two primary risk factors associated 
with Candida infections are colonization of the skin and mucous membranes and the 
presence of invasive devices.122  Candida colonization is not always treated and the 
urinary tract and upper airway may be colonized with Candida. Three patients with 
Candida infections in this study were not treated. One patient had Candiduria which was 
not treated and developed Candidemia three days later; however, the blood culture results 
were not complete until after the patient had expired. Another patient with Candidemia 
was not treated because care had been withdrawn before results were received, and 
another patient with Candidemia expired before results were received.  
 
Among all subjects developing infections, less than half (47%) developed fever or 
hypothermia, in contrast to 74.4% experiencing fever or hypothermia at initial 
presentation.  Fever in the ICU is one of the triggers that lead to a careful clinical 
assessment for its cause and possible laboratory assessments.54  Patients receiving 
corticosteroids have a blunted febrile response due to down-regulation of inflammatory 
mediators (IL-1β, TNF-α, IL-6) that cause fever. The threshold for laboratory assessment 
(blood culture, BAL, and others cultures) is lower in patients receiving corticosteroids,125  
which may explain why half of the infections were detected in the absence of fever. 
Meduri et al. identified 60% of infections occurring after ICU day seven in patients 
receiving corticosteroids in the absence of fever.126  The presentation of HAI required 
less fluid resuscitation and fewer vasopressors (17% vs. 32%), than their initial ICU 
presentation with sepsis.   
 
A significantly higher number of patients who received corticosteroids developed 
HAI compared to those who did not (82.4% vs. 42.6%, p = 0.005); however, when 
controlling for other factors (shown in AIM3) this was not significant. Overall, patients 
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who developed HAI had more invasive devices, more days of mechanical ventilation 
(11.1 vs. 5.9, p = 0.03) and more days of ICU stay (15.3 vs. 6.4, p < 0.0001) when 
compared to those who did not develop HAI. This is in agreement with literature which 
consistently shows high correlation of these variables with development of HAI.42 
 
 
Aim 1 
 
The primary goal of aim one was to investigate whether baseline protein 
expression levels of pro-inflammatory cytokines, anti-inflammatory cytokines, or their 
ratios influence the development of subsequent HAI in patients with sepsis.  
 
There were no significant differences in levels of pro-inflammatory cytokine, 
anti-inflammatory cytokine, or their ratio among subjects who did and did not develop at 
least one HAI during their ICU stay. Specifically, an exaggerated pro-inflammatory 
response was present in 6 (31.6%) compared to 11 (18.6%) participants without an 
exaggerated pro-inflammatory response who developed subsequent HAI. This difference 
was not significant (p = 0.55).  Likewise, an exaggerated anti-inflammatory response was 
present in 5 (26.3%) compared to 12 (20.3) participants without an exaggerated anti-
inflammatory response who developed subsequent HAI. This difference was also not 
significant (p = 0.43).  There was also no significant difference in the log of 
proinflammatory to anti-inflammatory ratios among those who did and did not develop 
subsequent HAI.     
 
One study investigated a similar relationship. Ramirez et al. performed a 
prospective observational study to examine the relationship between systemic 
inflammatory response and development of ventilator-associated pneumonia (VAP). 127  
They included patients on mechanical ventilation who were expected to remain on 
mechanical ventilation for more than 48 hours. They excluded patients who developed 
other HAIs. They measured several cytokine (IL-6, Il-10, and others) at baseline and then 
every 96 hours.  Their sample included 44 patients, among which 9 developed VAP.  
Findings included higher baseline IL-6 pg/ml among patients who subsequently 
developed VAP.  Higher median IL-6 pg/ml were reported for confirmed VAP cases (235 
(188-620)) as compared to non-suspected (92 (43 - 167)), suspected (120 (112 - 161)) 
VAP cases (p = 0.02). They found no significant difference in median IL-10 pg/ml for 
non-suspected (0 (0 - 4)), suspected (0 (0 - 4)), and confirmed (6 (3 - 12)) cases of VAP 
(p = 0.16). They reported IL-10 detection limits of 1pg/ml. 
 
 The findings of Ramirez provide limited evidence that a clinical relationship 
between exaggerated pro-inflammatory response and development of infections exists.127  
In our study, we were unable to identify a difference.  Our findings may be limited by the 
timing of cytokine measurement and other factors.  Baseline cytokine measurements were 
collected at enrollment within 72 hours of developing sepsis. IL-6 levels usually peak 
after IL-1β and TNF-α, around eight hours following an insult. The variation in timing 
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for each subject (0 – 72 hours) and use of corticosteroids ( < 1 mg/kg) may have limited 
these findings. 
 
 
Aim 2  
 
The goal of aim two was to investigate the variance in cytokine genes to 
determine if they influence levels of protein expression or development of HAI.   
 
 
Genotye and Cytokine Level 
 
We examined cytokine levels by genotype and compared subjects grouped by 
degree of inflammatory response. In Chi-square analysis comparing subjects with an 
exaggerated inflammatory response to those without an exaggerated response, we found 
no difference for rs1800795 or rs1800896. There were no significant differences in 
median or log IL-6 level based on genotype rs1800795.  We did find a significant 
difference in IL-10 level based on genotype rs1800896. Participants who were 
homozygous AA or GG had significantly higher log IL-10 levels than heterozygous GA 
genotypes (0.02).    
 
While promoter polymorphism may increase or decrease transcription levels, 
there are also epigenetic and other factors that influence gene regulation. Taudorf et al. 
studied the cytokine response to an endotoxin challenge in 200 young healthy men. They 
found up to a 6 fold increase in cytokine levels following endotoxin injection but they did 
not find significant differences in cytokine levels among many commonly studies 
cytokine SNPs, including rs1800896  and rs1800795.100  Among all comparisons 
involving genotype and cytokine level, we only found one difference. Other studies have 
shown varied results.  
 
Our findings, or lack of findings, may be limited by several factors. First, as noted 
in aim one, timing of cytokine measurement may be a factor. An underlying assumption 
of this research was that cytokine levels would be persistently elevated. This has been 
well documented in the literature, particularly for non-survivors.87-89 This assumption 
could not be evaluated in this study because plasma samples were only collected at 
baseline and not over time. Second, variability in cytokine measures may be a factor. 
This variability ranges from technician technique to the method selected for cytokine 
measurement to the various proprietary antibodies used by different biotech companies 
for each cytokine. Lastly, the findings of Taudorf suggest that either there may be no 
difference or, more likely, there are several other factors that may be involved such that 
these differences are not expressed in a healthier or less acutely ill population.  
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Genotype and Development of HAI 
 
There were no statistically significant differences among genotypes or haplotypes 
for development of HAI. There were no CC_AA, CC_GA, or GG_AA haplotypes among 
the 17 participants who developed HAI.  The CC_GG haplotype was not observed in 
another study.128 The most common haplotype was the heterozygous CG_GA.  Baier, et 
al., in a retrospective review of 293 low birth weight infants, investigated the IL-6 
rs1800795 and IL-10 rs1800896 SNPs and sepsis outcomes. In their study, the rs1800795 
C Allele was associated with late blood stream infections in African American but not 
Caucasian infants. The incidence of blood stream infections was 69% in African 
American infants with  the C Allele compared to 46% in African American infants with 
the GG genotype (p = 0.02). Racial differences have not been investigated in this 
dissertation study and will be explored in future analyses. Baier et al. also found an 
increased association of the rs1800896 A Allele with increased incidence of late blood 
stream infections.128 The rs1800795 CC genotype has been associated with fungal blood 
stream infections in Caucasians. This study population includes a large number of fungal 
blood stream infections. Among the 7 participants with the rs1800795 CC genotype only 
one developed a HAI, which was fungemia caused by Candida albicans. 
 
 
Aim 3  
 
The goal of aim three was to investigate the effects of protein expression levels, 
genetic variation, and environment on development of HAI.  A series of Cox regression 
analyses were performed among those who did and did not develop HAIs during ICU 
stay.  Although the univariate models provided important risk ratios, the multivariate 
model provides the variables most predictive for the risk ratio and can be used to predict 
the risk of HAI development. We found no difference in protein expression levels, one 
genetic variation, and two environmental factors that strongly predict risk of HAI 
development. The final model included APACHE II, invasive devise score, and 
antibiotics prior to ICU, and IL6 rs1800795.  
 
Severity of illness contributes to risk of HAI development. Based on the 
multivariate model, every one point increase in APACHE II score there is a 3.4% 
increase in the risk of developing HAI. APACHE II scores range from 0 to 71 with a 
higher scores associated with a worse outcome.38  The APACHE II has been correlated 
with baseline inflammatory response but not HAI development.12  Patients with a higher 
severity of illness require a higher level of care. These patients are potentially exposed to 
a higher risk due to the presence of more invasive devices and also have a higher 
exposure to multiple hospital personnel and equipment needed to provide their care. For 
each additional invasive device there was a 9.1% reduced risk in the development of 
HAI. This does not make intuitive sense. It is likely that the format of the invasive device 
score used in the model is problematic and additional models will be explored using only 
the number of invasive devices present at the time of HAI, rather than the cumulative 
score. Table 4-6 provides the cumulative invasive device score at the time of HAI (52.8 
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± 26.7) and Table 4-8 provides the cumulative invasive device score at ICU discharge 
(23.9 ± 23.0) for those who did not develop HAI. More investigation is needed to fully 
assess these findings. 
 
We found that early antibiotic use prior to ICU stay reduces risk of HAI in 
patients with sepsis. The importance of early antibiotic use has been incorporated into 
several guidelines. The surviving sepsis campaign recommends antibiotics within the first 
hour for septic shock.26 The IDSA recommends antibiotic administration in the ER prior 
to ICU admission for patients with CAP.55 In this study, we examined whether patients 
received antibiotics before transfer to the ICU.  The early administration of antibiotics 
reduces morality associated with sepsis and may, according to Zubert, be a “surrogate 
marker for quality of care in the broader sense”. 129  While early antibiotic use is 
important, appropriately deescalating therapy based on culture sensitivities is also 
important.130    
 
The presence of IL6 rs1800795 CC compared to GG and GC compared to GG had 
a higher risk in the univariate mode, and the risk increased in the multivariate model 
when controlling for other variables. The final model included only variables that were 
significant (p < 0.05). The higher risk associated with rs1800795 genotypes CG and CC 
is consistent with higher risk associated with the C allele noted in the literature. The 
rs1800795 C Allele has also been found to be associated with late blood stream infections 
in African American infants,128 and has been shown to be more prevalent in coronary 
artery patients developing myocardial infarction compared to coronary artery patients 
with stable and unstable angina.131    More analysis is needed to fully explore the 
relationships of these variables. 
 
 
Strengths 
 
Study strengths are summarized below:  
 
1. This study occurred in a teaching hospital where the attending physicians and 
medical team rotate monthly; however, the MICU team include a PharmD who is 
present for daily rounds with the team in the morning and afternoon on Monday 
through Friday. This provides consistency in patient management in regards to the 
appropriate use, selection, and dosing of antibiotics in the ICU. This PharmD 
reviewed cultures and antibiotics with me to determine appropriate antibiotics 
based on current guidelines. 
2. This study occurred in one facility, limiting the biases that could occur at multiple 
sites by multiple data collectors.  
3. The inclusion of biomarkers and use in a multivariate model strengthens 
conclusions about risk factors associated with development of HAI. 
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Limitations 
 
Study limitations are summarized below: 
 
1. A potential limitation of this study was the heterogeneous sample. Some patients 
were not as sick as others and were discharged from the ICU prior to three days.  
Since development of HAI has been strongly associated with length of stay, this is 
a limitation that was accounted for by using Cox regression modeling. 
2. Limiting this study to a single site with primarily older male veterans limits 
generalizability of findings.  
3. It was a major assumption that baseline systemic inflammation would be 
prolonged. Measuring only baseline cytokine levels is a limitation. 
4. The usage of corticosteroid therapy may impact the degree and duration of 
systemic inflammation; thus, potentially limiting the possible impact of systemic 
inflammation on the development of HAI in participants receiving corticosteroids. 
5. The use of corticosteroids may limit fever among participants experiencing HAI, 
and may result in failure to detect HAI when they occur. It is recommended 
clinical practice in our ICU to use sepsis surveillance, and thus a high degree of 
suspicion when steroids are used. 
6. There may be other predisposing factors for development of HAI that were not 
measured. 
7. The investigator is a novice bench researcher, and although efforts were made to 
accurately follow protocols, it is possible that errors could have influenced results.   
8. Endpoint genotyping of rs1800896 required manual calls in seven samples. 
9. Interleukin 6 was selected as a proinflammatory cytokine; however, it does have 
some anti-inflammatory properties. 
  
 
Implications  
 
This study provides important insights into risk factors that contribute to the 
development of HAI in patients presenting to the ICU with sepsis. These findings may 
impact nursing and other critical care clinician practice first by helping to identify 
patients at risk, then implementing stricter targeted infection control practices in efforts to 
prevent development of HAIs (in addition to current standard and recommended 
practices).  JACHO patient safety goals include prevention of HAI.   
 
Since the completion of this study, new processes are in place in the facility 
where this study occurred. These including daily surveillance of central line sites and 
implementation of a UTI bundle to reduce UTI. The findings of this study reveal a need 
to further investigate the cause of Candida in this population and to follow-up on the 
incidence of Candida in this unit. The use of antibiotic timing and duration should be 
reviewed.   A high percentage (9 of 11, 81.8%) of the Candida infections occurred during 
corticosteroids use, indicating a need to assure appropriate sepsis surveillance is followed 
in patients receiving corticosteroids. Specific nursing measures would include a review of 
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standard IV care practices such as tubing changes, site rotation for peripheral lines, 
duration of central lines, routine site evaluation and care, hub care, cleaning of IV 
equipment, cleaning of transducer holders, and no re-use of disposable pressure bags. 
This may include changing the catheter hub after blood draws when flushing cannot 
completely clear the hub as well as protocol driven hub care.  
 
Cleaning the environment closest to the patient needs to be considered. The side 
rails, call light, bed controls, and equipment in use in the room are typically only cleaned 
when they become soiled. These items could be wiped down with sanitary wipes daily 
when other areas of the room are cleaned. Cleaning of other environmental areas would 
include routine cleaning of medication carts, including the front of medication drawers, 
keyboard, scanner, and the work surface. Routine cleaning of the sink handles and light 
switches should also be evaluated. 
 
 
Conclusions 
 
This study provides evidence of a genetic risk for development of HAI. Despite 
best evidenced based practices some patients will develop HAI. Strict aseptic technique is 
essential to preventing infection. In addition to eliminating invasive devices as quickly as 
possible, patients with a high severity of illness may need to be isolated to lower their 
risk. Early administration of antibiotics not only provides prompt treatment for the initial 
infection but also lowers risk for subsequent infections.   
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